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„Die Erfindung ist Gegenstand der Kunst, der der 
Wissenschaft ist die Erkenntnis, die erstere findet 
oder erfindet die Tatsachen, die andere erklärt sie; 
die künstlerischen Ideen wurzeln in der Phantasie, 
die wissenschaftlichen im Verstande.“ 
 Justus von Liebig 
  
  
ABSTRACT 
The immune system, including innate and adaptive lymphocytes, is involved in determining 
the outcome of many human diseases. Two lymphocyte subsets, natural killer (NK) cells and 
T cells, which are present in both peripheral blood and in tissues, will be further discussed in 
the context of acute and chronic viral infections and inflammatory liver diseases in this thesis. 
NK cells are important players in the early defense against many viral infections. To improve 
our understanding of human NK cell responses in acute viral infections, we here 
comprehensively characterized peripheral blood NK cells in patients with acute dengue virus 
infection, causing dengue fever, from early after symptom debut (paper I). In particular, less 
mature NK cell subsets were robustly activated, and our data further suggested an IL-18-
dependent mechanism for driving the observed response. Responding NK cells exhibited a 
distinct chemokine receptor imprint indicative of skin homing and we could identify a 
corresponding NK cell subset in the skin from patients with acute infection. 
In chronic viral infections, such as chronic hepatitis B (CHB), NK cells and T cells are 
generally dysfunctional. This dysfunction may contribute to the hosts inability to clear the 
infection. Nucleos(t)ide analogue (NA) therapy suppresses hepatitis B virus (HBV) 
replication, but rarely cures CHB. Stopping long-term NA therapy leads to viral relapse and 
liver inflammation but eventually to functional cure in a fraction of patients. Here, we found 
that structured NA treatment discontinuation in CHB patients augmented peripheral blood 
NK cell natural cytotoxicity responses 12 weeks following treatment cessation. This 
enhanced functionality was associated with liver inflammation, particularly in patients with 
subsequent functional cure (paper II). Furthermore, T cells from the CHB patients achieving 
a functional cure displayed a more activated phenotype. In vitro stimulation with HBV-
specific peptides further revealed enhanced peripheral blood T cell functionality that could be 
boosted with PD-L1 blockade (paper III). 
In addition to the analyses of lymphocytes in peripheral blood, we investigated the role of an 
unconventional T cell subset, mucosal invariant T (MAIT) cells, in peripheral blood and bile 
ducts of patients suffering from primary sclerosing cholangitis. The immunological 
mechanisms in this rare chronic progressive inflammatory disease of the biliary tract are 
largely unknown. While MAIT cells were enriched in the bile ducts, numbers and function of 
circulating MAIT cells were strongly reduced (paper IV). 
Further analyses of the biliary tract immunological landscape revealed that TcRab CD8ab 
effector memory T cells represented the dominant intraepithelial immune cell population. 
These biliary-resident T cells co-expressed gut- and liver-homing receptors and displayed a 
Th1/Th17 functional profile (paper V). 
In summary, we could show a significant contribution of NK cells and T cells to the immune 
response in acute and chronic viral infections, whereas the characterization of biliary-resident 
T cells has just begun and their function in immunopathogenesis remains to be explored. 
Altogether, the investigation of immunological mechanisms underlying a variety of human 
diseases adds to our understanding of human immune cell functionality as well as presents 
strategies for future treatment development.  
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1 INTRODUCTION 
1.1 THE HUMAN IMMUNE SYSTEM 
The body has various defense mechanisms against infections that together build up the 
human immune system. The immune system protects against viruses, bacteria, fungi and 
parasites and is comprised of various cellular effectors (leukocytes) and the humoral arm. 
After birth, most leukocytes are derived from pluripotent hematopoietic stem cells of the 
bone marrow that give rise to a common progenitor of the lymphoid and myeloid lineage. 
The immune system can further be divided into the innate and the adaptive immune system. 
In general, the innate immune system provides immediate protection in a nonspecific way. 
Germline-encoded receptors recognize unique microorganism-associated conserved features. 
In contrast, the adaptive immune response is initiated later, performs an antigen specific-
recognition mediated by re-arranged receptors from gene segments via somatic 
recombination, and is able to create immunological memory. The interplay of both the innate 
and adaptive immune system is crucial for mounting an effective immune response, but also 
for the discrimination of self from non-self (1-3). 
1.1.1 The innate immune system 
Epithelial cells, such as in the skin and the gastrointestinal tract, are considered to be the first 
line of defense. Epithelia are physical barriers, being able to secrete mucus and are equipped 
with other chemical and anti-microbial properties. Furthermore, they are populated with the 
common microbiota that shapes the immune system, but also competes with pathogens for 
space and nutrients (4). Once an infection has established, the infectious agent may be 
contained locally or spread throughout the body.  
Microorganisms are recognized by pathogen-recognition receptors (PRRs) expressed by a 
variety of cells, including epithelial cells, tissue-resident mast cells, macrophages and 
dendritic cells (DCs). PRRs detect pathogen-associated molecular patterns (PAMPs) that are 
shared by several classes of microorganisms. Toll-like receptors (TLRs) are a well-
characterized example. These receptors are located on the cell surface or intracellularly and 
recognize viral nucleic acid and bacterial products, for example lipopolysaccharide (LPS). 
TLR activation induces pro-inflammatory cytokine production, including tumor-necrosis 
factor (TNF), interleukin (IL)-1b and IL-6, which initiate inflammation. IL-1b and TNF 
activate the endothelium of local capillaries, allowing recruitment of leukocytes to the site of 
infection as well as enabling serum proteins, such as complement proteins, to enter the tissue. 
Activation of the complement system causes proteolytic cleavage of complement proteins, 
leading to the covalent attachment of the cleavage product C3b on the target cell. C3b acts as 
an opsonin and initiates the creation of the membrane attack complex, which facilitates a pore 
causing cell lysis. Cleavage products (C3a, C5a) act as anaphylatoxins and promote 
inflammation (3). Moreover, accumulation of tissue factor initiates the local coagulation 
cascade to avoid pathogen dissemination. Other PRRs are located intracellularly. These 
include receptors, such as NOD-like receptors (NLRs) that are involved in inflammasome 
activation, thereby initiating caspase-mediated activation of IL-1 family cytokines (IL-1b, IL-
18, IL-33), but also sensors of double-stranded cytoplasmic viral nucleic acids, retinoic-acid-
inducible gene I (RIG-I) and melanoma differentiation-associated gene 5 (MDA5). The 
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activation of RIG-I and MDA5 causes type I interferon (IFNa, IFNb) production and 
subsequent expression of IFN-inducible genes with products triggering an anti-viral state 
(1, 2). Local immune cells, including innate lymphoid cells (ILCs, NK cells/ILC1-ILC3), are 
activated early by the cytokine milieu created and shape subsequent immune responses (5). 
Another mechanism in innate immunity is phagocytosis, which plays an important role in 
pathogen killing with the most efficient cells being neutrophils and macrophages mostly 
fighting infections with fungi/extracellular bacteria and intracellular bacteria, respectively. 
Multicellular parasites get eliminated by tissue-resident mast cells releasing mediators, such 
as histamine, serine proteases, and various enzymes, or by eosinophils and basophils that get 
recruited from the circulation. DCs, which are professional antigen presenting cells (APCs), 
play an important role in bridging innate and adaptive immune responses. They survey 
peripheral tissues, detecting and phagocytosing pathogens, which are processed and may lead 
to DC activation and cytokine production. Activated DCs then migrate to local secondary 
lymphoid tissue, and initiate adaptive immune responses (1, 3). 
1.1.2 The adaptive immune system 
Adaptive immune responses are classically initiated in a well-coordinated fashion in 
secondary lymphoid tissues where naïve T cells and B cells reside in distinct areas and 
eventually encounter their cognate antigen (6). Peptide antigens are displayed by APCs in 
complex with major histocompatibility complex (MHC) class I or II (human leukocyte 
antigen (HLA) in humans) to T cells. Activation is followed by clonal expansion and 
differentiation, generating antigen-specific effector T cells and antibody secreting B cells. B 
cell responses are initiated in a T cell-dependent or independent fashion and accompanied by 
class-switch recombination in B cell follicles and somatic hypermutation in germinal centers, 
resulting in generation of memory B cells or long-lived plasma cells (6). T and B cells egress 
via efferent lymphatics before returning into the blood stream from where they can enter the 
site of infection. Antibodies neutralize and opsonize pathogens, which in turn promotes 
phagocytosis and complement activation. Fc receptor-bearing innate effector cells can 
recognize antibody-coated cells, release microbicidal factors or directly kill the opsonized 
pathogen via antibody-dependent cellular cytotoxicity (ADCC), which is mediated by the 
effector cells of the innate immune system, linking the innate and adaptive immune response. 
Effector T cells can either be cytolytic and/or release cytokines of different action, affecting 
the innate immune response. The resolution of an infection is followed by a contraction phase 
during which most effector lymphocytes die. However, a small number of memory cells 
persist for years, being poised for an accelerated adaptive immune response in case of 
subsequent encounter with the same pathogen (1, 3). 
1.2 HUMAN LYMPHOCYTE IMMUNOLOGY 
1.2.1 Natural killer cells 
Human natural killer (NK) cells belong to the group of type 1 ILCs that commonly lack 
somatically recombined antigen receptors, produce IFNg and require the transcription factor 
T-bet for their development (7). NK cells were discovered in 1975 by Rolf Kiessling as well 
as Ronald Herbermann and colleagues. NK cells were initially described as lymphocytes with 
naturally occurring killer activity, being able to eliminate their target cells without prior 
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sensitization (8-10). Closer insights into the mechanism involved in this natural killer activity 
were proposed by Klas Kärre et al. in 1986 (11, 12). He suggested that, as opposed to T cells, 
NK cells recognize and kill their targets in the absence of MHC class I molecules, a 
mechanism termed the “missing-self hypothesis” (11-13). MHC class I molecules may be 
lost upon cellular stress or viral infection, but are expressed by most healthy nucleated cells in 
steady-state conditions, ensuring tolerance to self. 
Today, NK cells are well known for their important role in the early response against viral 
infections and malignant transformed cells. Besides their killing capacity, NK cells exhibit an 
immunoregulatory function by producing cytokines and chemokines (14, 15). NK cells 
comprise approximately 10% of all lymphocytes in peripheral blood, but are also present with 
varying frequencies in many peripheral tissues, such as liver, gut, and skin (16). Most studies 
on tissue-specific NK cells have been performed in mice. However, significant differences in 
NK cells between humans and mice limit the extrapolation of murine data to the human 
system. In detail, human NK cells are defined by the lack of CD3 and expression of CD56. 
NK cells are divided into two main subsets based on the differential surface expression of 
CD56 and the Fcg receptor IIIA (CD16): CD56bright and CD56dim NK cells (7). Since CD56 is 
not expressed on murine NK cells, NK1.1 (CD161) is used instead for the identification of 
murine NK cells, and CD27 and CD11b for discrimination of distinct NK cell subsets in 
mice. 
NK cell subsets differ in phenotypic and functional properties both in mice and in humans, 
and how they are distributed throughout the human body. Human CD56dim NK cells comprise 
roughly 90% of peripheral blood NK cells, express high levels of CD16 and are, at steady 
state, described to be more cytolytic and target-cell responsive (14, 15). In contrast, 
CD56bright CD16dim or CD56bright CD16neg NK cells are strongly responsive to inflammatory 
cytokine-stimulation and mainly possess immunoregulatory functions (17). However, 
stimulation can rapidly induce lytic properties in CD56bright NK cells and 
cytokine/chemokine-secreting functionality in CD56dim NK cells (14, 15). 
1.2.1.1 Regulation of NK cell Functionality 
NK cell activation and function is regulated by signal integration of activating and inhibitory 
receptors (14, 18). In this process, varying signal strength can impact the type and 
multiplicity of the NK cell response. Moreover, NK cell effector responses are underlying a 
hierarchical order. Stimulatory requirements for CD56bright and CD56dim NK cells vary based 
on different properties in regard to their cytokine responsiveness and receptor expression (15, 
19). Numerous NK cell activating and inhibitory receptors and their respective ligands have 
been identified (14, 18, 20). In the following, the most relevant ones for this thesis are 
highlighted (Table 1).  
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         Table 1: NK cell receptor-ligand pairs 
Receptors Ligands 
Activating  
 NKG2D MICA, MICB, ULBP-1-4 
DNAM-1 PVR (CD155), Nectin-2 (CD112) 
NKp30 B7-H6, HSPG 
NKp44 Viral hemagglutinin 
NKp46 Viral hemagglutinin 
CD16 IgG 
CD94/NKG2C HLA-E 
KIR2DS1 HLA-C2 
KIR2DS2 HLA-C1 
KIR2DS4 HLA-A11 (some HLA-C, HLA-F) 
KIR3DS1 HLA-Bw4, HLA-F 
 
  
Inhibitory 
 KIR2DL1 HLA-C2 (lysine at position 80) 
KIR2DL2/3 HLA-C1 (asparagine at position 80) 
KIR3DL1 HLA-Bw4 
KIR3DL2 HLA-A3, HLA-A11, HLA-F 
CD94/NKG2A HLA-E 
Siglec-7 Sialic acid 
CD161 LLT-1 
 
Human NK cells identify “self” cells via recognition of the HLA class I molecules (HLA-A, -
B, -C) by killer cell immunoglobulin-like receptors (KIRs) with recent evidence of an 
interaction of KIRs with the non-classical HLA molecules HLA-G and -F (21-24). As 
mentioned above, virus-infected or transformed cells often downregulate HLA class I 
molecules to avoid T cell recognition, which results in the lack of the inhibitory signals 
suppressing the NK cell (18). The nomenclature of KIRs is based on their structure with a 
specified number of extracellular Ig-like domains and information about the cytoplasmic 
domain that can be long (L) or short (S). Inhibitory signals are transmitted via 
immunoreceptor tyrosine-based inhibition motifs (ITIMs) located directly in the long 
intracellular domain, and activating signals via adaptor molecules containing immunoreceptor 
tyrosine-based activation motifs (ITAMs) that are associated with short intracellular domains. 
After receptor-crosslinking, ITIMs get phosphorylated and recruit tyrosine-phosphatases that 
in turn shut down activation by dephosphorylation of activating adaptor molecules (21). KIRs 
have HLA class I allotypes as ligands with the most important for this thesis being listed in 
Table 1. The KIR locus is highly complex, being highly polygenic and polymorphic (25), 
with KIR-S genes being interspersed with KIR-L genes. Based on the presence of certain 
genes, two KIR haplotypes have been defined as group A and B. Haplotype A only consists 
of inhibitory genes except KIR2DS4, whereas haplotype B contains combinations of 
inhibitory and activating genes (21, 26). Moreover, KIRs are expressed stochastically and 
thereby contribute to NK cell diversity (26). 
NKG2-receptors are highly conserved C-type lectin receptors with seven members of this 
receptor family. Both NKG2A and NKG2C form heterodimers with CD94 and interact with 
the non-classical HLA-E molecule (27). NKG2A has an inhibitory function with an ITIM 
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motif in its cytoplasmatic tail (28), whereas NKG2C is an activating receptor, being 
associated with DAP12 containing ITAMs (29). NKG2D is another member of the same 
family exhibiting an activating function. As opposed to NKG2A and NKG2C, NKG2D forms 
a homodimer and binds to the stress-induced ligands MHC class I polypeptide-related 
sequence (MIC)A/B and UL16 binding protein (ULBP)1-4 (30, 31). 
Similarly, another NK cell activating receptor, DNAX accessory molecule (DNAM)-1 
(CD226), has been shown to bind to stress-induced ligands. DNAM-1 interacts with PVR 
(CD155) and Nectin-2 (CD112) (32). The expression of DNAM-1 is coordinated with the 
conformational change of lymphocyte function-associated antigen (LFA-1) and both DNAM-
1 and LFA-1 co-localize at the immune synapse, contributing to enhanced effector functions 
(33). 
Natural cytotoxicity receptors (NCRs) include, but are not limited to, NKp30, NKp44, and 
NKp46. On human NK cells at steady state, NKp30 and NKp46 are widely expressed, in 
contrast to NKp44 that is expressed on activated NK cells or non-NK cell ILCs. NCRs are 
part of the Ig superfamily and associate with different intracellular adaptor molecules (CD3z, 
DAP-12, FceRIg) (34). Their ligands are not well-defined, but have been suggested to be 
tumor-associated molecules (e.g. B7-H6) and viral hemagglutinins, the latter recognized by 
NKp44 and NKp46 (35, 36). 
TNF-related apoptosis-inducing ligand (TRAIL) belongs to the TNF family and represents 
together with FasL (binding Fas/CD95) a death receptor that induces apoptosis and is 
upregulated upon exposure to type I IFN. TRAIL forms homodimers and binds to DR4 
(TRAILR1), DR5 (TRAILR2) and soluble TRAIL receptors (decoy receptors). Apoptosis is 
induced via a caspase-8-dependent caspase cascade (37). 
CD16 (FcgRIIIa) is a NK cell activating receptor highly expressed on CD56dim NK cells, 
mediating ADCC. CD16 signals after binding and crosslinking the Fc part of IgG antibodies 
via its intracellular tail that is associated with the FceRIg and CD3z adaptor molecules 
containing ITAMs (38). 
Additionally, the cytokine environment and interactions with other immune cells such as T 
cells, DCs, and macrophages influence the quality of the NK cell response (39, 40). 
Cytokines produced by other immune and non-immune cells can directly activate NK cells. 
The main environmental activating cues NK cells respond to are type I IFNs, IL-2, IL-12, IL-
15, and IL-18 (14). Type I IFNs have been shown to enhance cell-mediated cytotoxicity, 
whereas IL-12 and IL-18 enhance IFN-g production in a synergistic manner. IL-2 and IL-15 
instead primarily induce proliferation and promote survival of NK cells. In contrast to NK 
cell-activating pro-inflammatory cytokines, both IL-10 and transforming growth factor 
(TGF)-b that are present especially in the tumor environment but also healthy peripheral 
tissues, suppress NK cell activity and effector responses (14). 
NK cell effector responses include direct killing of target cells via ADCC, death receptor 
mediated cytolysis (FasL- or TRAIL-mediated) or the release of cytotoxic granules (perforin 
and granzymes). Perforin inserts a pore into the target cell membrane, allowing granzymes to 
enter and cleave intracellular proteins, ultimately leading to apoptosis of the target cell (37). 
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ADCC allows NK cells to directly kill antibody-tagged cells, but they can also modulate the 
inflammation-associated immune response by directly killing APCs and T cells (14). Apart 
from being cytotoxic, NK cells have the capacity to release cytokines, chemokines and 
growth factors, including IFNγ, TNF, CC-chemokine ligand 3, 4 and 5 (macrophage 
inflammatory protein (MIP)-1a, MIP-1b, and RANTES, respectively), and granulocyte–
macrophage colony-stimulating factor (GM-CSF) (15). Hereby, effector responses follow a 
temporal hierarchy with degranulation and chemokine secretion being early features followed 
by cytokine release at later time points (15). Thus, NK cells integrate both cytokine priming 
and synergistic activation through receptor co-engagement, which ultimately determines the 
response as immune-regulators and/or direct effectors (15, 38).  
1.2.1.2 NK cell differentiation and education 
NK cells arise from a common lymphoid progenitor. The transcription factors inhibitor of 
DNA binding 2 (ID2) and E4BP4 have been proposed to specify NK cell lineage precursors, 
and IL-15 is known to be important for NK cell development (41). During maturation, NK 
cell progenitors lose CD34 and CD117 (c-kit) and acquire CD94, CD16, and KIRs that 
distinguishing them from other ILC family members (42). A recent attempt trying to identify 
a NK cell-restricted precursor that separates them from CD127+ ILCs has been made (43). In 
fetal tissue, neonatal cord blood, and in adult tissues such a precursor 
(CD34+CD38+CD123−CD45RA+CD7+CD10+CD127−) was identified lacking lineage 
markers for T and B cells as well as myeloid cells. These precursor NK cells have the 
capacity to develop into T-bet+ Eomesodermin (Eomes)+ NK cells but not CD127+ ILCs in 
vitro (43). Eomes and T-bet are T-box family transcription factors known for their 
complementary role during NK cell development. Higher levels of Eomes are associated with 
less mature NK cells and higher levels of T-bet are associated with more terminally 
differentiated NK cells (44). Several studies indicate that CD56bright NK cells differentiate 
into CD56dim NK cells in a final step during maturation (45-47), a model of differentiation 
that is challenged by results from macaques (48). During maturation, a process termed NK 
cell education (or licensing), greatly impacts NK cell functionality. This process requires the 
recognition of HLA class I ligands by their respective receptors (KIRs or NKG2A, that are 
mostly inhibitory except KIR2DS1) (49-51). NK cell licensing arms the maturating cells for 
full functionality, whereas unlicensed NK cells are rendered hypofunctional. This preserves 
self-tolerance against normal cells in the missing self-setting. The inhibitory signal strength 
(based on the number of KIRs and the allele) during education quantitatively controls NK cell 
effector functions, thereby fine-tuning NK cell responses (23, 52). In addition to education, 
NK cells undergo a differentiation process accompanied by phenotypical changes as 
indicated by the altered surface expression of CD57, NKG2A, and KIRs as well as changes in 
the functional capacity. CD56bright NK cells express NKG2A, which is lost during 
differentiation while CD57 is expressed on more terminally differentiated NK cells. In 
addition, KIRs are sequentially acquired during the differentiation process, contributing to 
education, which occurs in parallel to differentiation. On a functional level, less differentiated 
NK cells respond well to cytokines and proliferate, while more differentiated NK cells 
gradually lose this capacity and instead become more cytotoxic (47) (Figure 1). 
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Figure 1: NK cell differentiation is associated with phenotypical and functional changes. 
Adapted from Björkström et al. (47), Long et al. (38), and Bernardini et al. (53) 
1.2.2 T cells 
1.2.2.1 Conventional T cells  
T cells are adaptive lymphocytes that develop in the thymus. The vast majority of T cells uses 
the ab chains for T cell receptor (TCR) assembly, whereas a minority uses the gd chains (3). 
During maturation, T cells acquire their unique TCR via somatic V(D)J recombination using 
recombination-activating gene (RAG)1 and RAG2. The TCR associates with the CD3 
complex (ge, de heterodimers and the z homodimer chain) that contains ITAMs for signal 
transduction (3). The expression of a functional TCR is accompanied by the expression of the 
co-receptors CD4 and CD8. A selection process, termed positive selection, ensures that only 
MHC-restricted T cells survive that bind to the MHC molecule with sufficient affinity, but do 
not recognize self-antigens (negative selection). T cells become CD8 or CD4 single positive 
and exit the thymus. The decision which co-receptor is expressed depends on the type of 
MHC molecule the T cell interacts with. T cells binding to MHC class I or II become 
cytotoxic T cells that express CD8 or T helper cells (Th0) expressing CD4, respectively (54). 
Peptides presented in complex with MHC molecules results in functional priming of T cells 
(signal 1). However, co-stimulatory signals (signal 2) are required for T cells to become fully 
activated, such as CD28 expressed on T cells binding to B7.1 (CD80) and B7.2 (CD86) 
expressed by APCs. Lack of co-stimulation may lead to T cell apoptosis or anergy (T cell 
hyporesponsiveness), a mechanism to ensure immune tolerance (55). 
13-24 amino acids long peptides from extracellular pathogens are presented to naïve CD4+ T 
helper (Th) cells in secondary lymphoid organs. Here, T cells receive cues from APCs in 
form of polarizing cytokines (signal 3), which direct T cell differentiation into subsets 
(Figure 2) (56). Th cells orchestrate immune responses by secreting cytokines and 
chemokines, provide B cell help for antibody production, and recruit other immune cells to 
the site of infection (56). A Th cell has a characteristic cytokine profile, resulting in a subset-
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specific effector response. Th1 cells are important for cell-mediated immune responses to 
intracellular pathogens and mainly secrete IFNg. IFNg is a potent inflammatory cytokine with 
many functions including MHC and TLR upregulation, increased phagocytosis and 
macrophage activation, IgG antibody class switch, and chemokine secretion. Th2 cells are 
involved in the defence against multicellular parasites and contribute to the development of 
allergies. Th2 responses are characterized by the key cytokines IL-4, IL-5, and IL-13, which 
mediate antibody class switch (IgG1, IgE), DC and macrophage maturation, as well as mucus 
production. Th17 cells classically secrete IL-17 and IL-22 involved in the response towards 
extracellular bacteria and fungi by attracting neutrophils and inducing inflammatory 
mediators and antimicrobial peptides (AMPs). Regulatory T (Treg) cells have a regulatory 
function and secrete anti-inflammatory cytokines, such as IL-10 and TGF-b. More recently, 
Th22 and Th9 cell subsets were identified by the production of IL-22 and IL-9, respectively. 
Th cell subsets are induced by key cytokines that signal via signal transducer and activator of 
transcription (STAT) proteins. Moreover, specific transcription factors define the respective 
Th cell-subset (Figure 2) (57, 58). 
 
Figure 2: T helper cell subset differentiation is driven by polarizing cues and results in 
subset specific effector responses. Adapted and modified from Zhu et al. (56), Raphael et al. 
(57), Schmitt et al. (58) 
CD8+ T cells recognize 8-10 amino acid long peptides that are derived from intracellular 
pathogens or are cross-presented by DCs. Cross-presentation is the re-direction of exogenous 
antigens into the MHC class I pathway, a process for inducing immune responses against 
tumors and non-APC-infecting viruses. CD4+ T cells may provide help to induce a robust 
CD8+ T cell response, either indirectly via CD40-CD40L interaction for functional 
maturation of DCs or by a direct interaction between the CD4+ and the CD8+ T cell. In 
infections with TLR engagement that induce a strong type I IFN response, CD4+ T cell help 
may be dispensable. Upon activation, CD8+ T cells expand strongly and differentiate into 
cytolytic effector T cells, which can kill their targets directly via the release of cytotoxic 
granules (granzymes and perforin) and death receptors (TRAIL, FASL) or indirectly by the 
secretion of cytokines and chemokines, such as IFNg, TNF, IL-2 and MIP-1b (59-61). 
After pathogen clearance, most T cells die in the contraction phase. However, a small fraction 
of the T cells survives and is maintained as long-lived memory cells, a process that is 
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accompanied by epigenetic reprogramming and changes in the metabolism of the cell. 
Immunological memory is the ability to quickly mount efficient recall responses upon 
encountering with the same pathogen (59, 62, 63). Despite being extensively studied, the 
differentiation of memory T cells is not fully understood (63). Murine models demonstrated 
that CD8+ T cell effector functions and memory formation are regulated by the transcription 
factors T-bet and Eomes (64, 65). Accumulating evidence suggests that the CD8+ T cell long-
term fate is determined by the expression ratio of the transcription factors T-bet and Eomes 
that drive effector functions and memory development, respectively (63). Unlike for naïve T 
cells, TCR signalling is largely insignificant for memory T cell homeostasis, which is mainly 
dependent on IL-7 and IL-15 (66). Memory T cells are divided into functionally different 
subsets with distinct homing capacity and effector functions: central memory (TCM), effector 
memory (TEM) (67), terminally differentiated effector memory (TEMRA), and tissue-resident 
memory (TRM) cells. TRM cells are located in mucosal tissue and do not re-circulate (61, 62, 
68). The expression of C-C chemokine receptor type (CCR)7 and CD45RA (67), or 
alternatively CD62L and CD45RO, is commonly used to distinguish between memory 
populations (Tnaive: CCR7+ (CD62L+) CD45RA+ (CD45RO-), TCM: CCR7+ (CD62L+) 
CD45RA- (CD45RO+), TEM: CCR7- (CD62L-) CD45RA- (CD45RO+), TEMRA: CCR7- 
(CD62L-) CD45RA+ (CD45RO-)). TCM primarily recirculate through secondary lymphoid 
organs, have the greatest proliferative potential, mainly produce IL-2, and can rapidly expand 
and differentiate upon re-challenge due to their high sensitivity to antigen stimulation and 
their reduced requisite for co-stimulation (61, 69). Similar to naïve T cells, TCM express 
CCR7 and CD27/CD28, which are important for secondary lymphoid tissue entry and co-
stimulation. TEM/TEMRA circulate between secondary lymphoid organs and peripheral 
inflamed tissues with the capacity to rapidly mount effector responses. CD8+ TEMRA are most 
well equipped with perforin followed by CD8+ TEM. In blood, TCM are predominantly CD4+ 
and TEM CD8+ T cells, whereas the subset ratio in the periphery is tissue-dependent with a 
TEM dominance in peripheral organs, such as lung, liver, and gut (61). 
1.2.2.2 Mucosal associated invariant T cells 
T cells that do not recognize classical peptide antigens are considered unconventional, for 
example CD1d-restricted NKT cells, gd T cells, and mucosal-associated invariant T (MAIT) 
cells. In contrast to conventional TCRab T cells, these unconventional T cells are poised for 
rapid effector responses with a tendency to localize in non-lymphoid tissue (70). MAIT cells 
are innate-like T lymphocytes that primarily contribute to anti-bacterial immunity and might 
play a role in sterile inflammation and cancer (71). In humans, they represent a minor fraction 
of total blood T cells (~5%) but are enriched at mucosal sites, particularly the liver where 
they account for up to 30% of all intrahepatic T cells (72-74). MAIT cells are characterized 
by the expression of the semi-invariant TCR (TCR-Va7.2-Ja33 (Ja12/20)) that recognizes 
the non-polymorphic MHC-related protein 1 (MR1). Unlike the Va chain, the Vb chain can 
vary (but is mostly Vb2 and Vb13.2) and contributes to the functional outcome of the TCR-
MR1 interaction (75). By flow cytometry, MAIT cells can be defined as CD3+ TCR Va7.2+ 
CD161+ (CD4-) lymphocytes that are mainly CD8+CD4- or double negative. Alternatively, 
MAIT cells can be identified using a fluorochrome-coupled MR1-tetramer (76). MR1 binds 
unstable pyrimidine intermediates derived from a biosynthetic precursor of riboflavin 
(vitamin B metabolites), a biosynthesis pathway that exists in many bacteria, but not in 
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humans (77, 78). The bacterial ligands for MAIT cells are produced by a variety of bacteria 
that contain the riboflavin synthetic pathway, such as Escherichia (E.) coli, Salmonella, 
Staphylococcus aureus, and Klebsiella pneumoniae as well as some yeast species, for 
example Candida albicans. Human peripheral MAIT cells mostly show a TEM phenotype, 
express the transcription factors promyelocytic leukemia zinc finger (PLZF), T-bet, retinoid-
related orphan receptor (ROR) gt, high levels of IL-18Ra and the chemokine-receptors 
CCR2, CCR5, C-X-C chemokine receptor type (CXCR)6, CCR6, and CCR9 for tissue-
homing. Besides stimulation via the TCR, the cells can also get readily activated by innate 
cytokines such as IL-12 and IL-18, leading to proliferation and IFNg production (71, 72, 79). 
Additionally, the MAIT cell response can be potentiated by co-stimulation via CD28 (80). 
MAIT cells also produce other pro-inflammatory cytokines including TNF and IL-17, that 
may play a role in inflammatory diseases, for example inflammatory bowel disease (IBD), 
psoriasis, or rheumatoid arthritis (RA) (71, 79). Interestingly, human liver MAIT cells 
express high levels of IL-7R, and IL-7 produced in the liver potentiates TCR-dependent 
secretion of Th1 cytokines and IL-17 (74). Activated MAIT cells have the capacity to kill 
target cells via the release of cytotoxic granules containing granzyme B and perforin (81-83). 
Thus, MAIT cells can directly act anti-bacterially via the production of cytokines or by 
elimination of infected cells, but they can also recruit and stimulate other immune cells, for 
example neutrophils via IL-17 release (71). Notably, accumulating evidence suggests that 
MAIT cell effector functions vary in different tissue locations (74, 84-86) and can be 
heterogeneous in their response to different microbes (75). 
1.3 LYMPHOCYTE HOMING TO PERIPHERAL TISSUES 
The location of leukocytes in tissue plays a fundamental role in the immune responses. 
During inflammation, immune cells get recruited to peripheral organs via a multistep 
extravasation cascade involving rolling, firm adhesion, and chemotactic signals that are 
mediated by selectins, integrins, and chemokines, respectively. Classical examples for 
corresponding interaction are the inflammation-induced selectins E- and P- selectin or the 
interaction of LFA-1 (CD11a/CD18) binding its ligand intercellular adhesion molecule-1 
(ICAM-1) (87, 88). Chemokines are chemotactic cytokines that bind to their respective 
receptors on leukocytes and guide them to distinct anatomical locations during homeostasis 
and inflammation, a process referred to as homing (89). Chemokine receptors are 7-
transmembrane G-protein-coupled receptors that are differentially expressed on leukocytes 
(90). Chemokine binding results in a conformational change of the receptor, initiating 
intracellular signaling events that induce cell polarization, migration and adhesion (53). This 
is followed by the localization to a specific tissue-microenvironment based on a network of 
chemokine gradients present within the tissue (53). 
As innate sentinels, NK cells are widely distributed throughout the body and CD56bright NK 
cells in particular are enriched in most human tissues. NK cells are recruited in an organ-
specific manner, exhibiting tissue-specific functions (16, 91). Intriguingly, chemokine 
receptors are differently expressed on CD56bright and CD56dim NK cells and chemokine 
receptor expression is also modified throughout NK cell differentiation and during NK cell 
activation (47, 53). CD56bright NK cells express higher levels of CCR7, CXCR3, CCR5, 
CCR2, and CXCR4 that is also reflected by their presence in for example lymph nodes, liver, 
skin, and bone marrow, whereas CD56dim NK cells dominantly express CX3CR1 and 
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CXCR1 (53). Most studies addressing tissue-resident NK cells have been performed in 
mouse models with the help of knockout strains and blocking antibodies. In humans, studies 
describing chemokine-chemokine receptor interaction at inflammatory sites have been 
informative to understand NK cell migratory properties, but our knowledge of NK cell 
homing is incomplete (87) (Table 2). 
1.4 TISSUE-RESIDENT LYMPHOCYTES 
Recent studies have revealed the importance of non-circulating populations residing in 
peripheral tissues and highlighted some the differences between tissue-resident and 
circulating populations (92-99). Tissue-resident lymphocytes mediate local immune 
responses and include ILCs, TRM cells, unconventional T cells, and intra-epithelial 
lymphocytes (IELs) (100-102). Phenotypically, tissue-resident cells can be identified by 
expression of CD69, CD49a (forms a heterodimer with b1 integrin (CD29)) that binds to type 
IV collagen, and CD103 (forms a heterodimer with b7 integrin) binding E-cadherin on 
epithelial cells (Figure 3). The expression of CD103 is induced by TGF-b and has been 
shown to be important for survival, retention, and tissue localization of lymphocytes (16, 
100). Studies in mice have shown that the differentiation into tissue-resident T cells is 
controlled by a network of transcription factors (103). Kruppel-like factor 2 (KLF2), which 
drives the expression of L-selectin (CD62L) as well as S1PR1 (sphingosine 1-phosphate 
receptor 1) that are both involved in tissue egress, is down-regulated (104). Similarly, the 
expression of CD69 counteracts the expression of S1PR1 (105). Both T-bet and Eomes have 
been described to be down-regulated with residual T-bet expression for IL-15 responsiveness 
(106). Moreover, Homolog of Blimp-1 (Hobit) and Blimp-1 cooperatively repress genes for 
tissue-egress (107). A recent study investigating the human core transcriptional signature of 
TRM cells in lung and spleen confirmed an up-regulation of the phenotypical marker CD69, 
CD49a, and CD103 in addition to PD-1 and CXCR6 and also verified the lower expression of 
KLF2, S1P, and CD62L (Figure 3). However, Hobit expression was low (99). 
IELs are located at mucosal sites, where they act as sentinels, patrolling the tissue to maintain 
tissue integrity and provide direct (innate-like) effector functions upon local challenges (108-
110). Thymic agonist selection leads to the development of natural (n)IELs expressing the 
CD8aa homodimer in mice, whereas the existence of nIELs in humans is still controversial 
(108, 109). CD8aa has been described to function as a repressor of activation, which might 
fine-tune the activation threshold of nIELs to self-ligands (101). Alternatively, mature T cells 
expressing CD4 or CD8ab might be induced to become IELs in the periphery (101, 108, 
109). Their maintenance does not depend on prolonged antigen exposure (97). Instead, IL-7 
and IL-15 mediate survival and proliferation (110). TCRab T cells and TCRgd T cells are 
common within the IEL population and are well-characterized in the gut, where they have 
been shown to impact mucus composition, produce growth factors and stimulate AMP 
secretion by epithelial cells (111). Besides their protective role in the prevention of infections, 
IELs can directly lyse infected cells via granzymes and perforin or FasL. Cytolysis can be 
activated in a TCR-dependent fashion or NKG2D/NKG2C-mediated during cellular stress. 
Furthermore, IELs have the capacity to secrete various cytokines, such as IFNg, TNF, IL-2, 
IL-17, and IL-22, and chemokines to recruit additional leukocytes (109-111). Dysregulation 
of IELs, if not tightly controlled, causes loss of epithelial barrier integrity and is associated 
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with the susceptibility to infections and chronic inflammatory disorders, such as IBD and 
coeliac disease. In coeliac disease, for example, the increased production of IL-15 upregulates 
NKG2D/C causing cytolysis or lowers the threshold for TCR-mediated signaling without 
cognate antigen being present (102, 108, 110). Notably, several studies revealed that the IELs 
population is shaped by the tissue-dependent environmental cues (97, 98, 109, 110). 
Although IELs have been characterized in many organs, including the intestine, lung, skin, 
and liver (110, 112-115), distinct niches still remain to be explored, especially in humans, 
which is of importance for targeting the immunological constituent of various disorders. 
 
Figure 3: Mechanisms for memory T cell circulation and tissue-residency. TRM cell 
development is associated with a specific set of transcription factors and the expression of 
CD69, CD49a, and CD103. Egress factors mediate tissue exit of TEM cells. Adapted and 
modified from Schenkel et al. (68), Kumar et al. (99), Mackay et al. (103), and Masopust et 
al. (116). 
1.5 THE LIVER AS AN IMMUNOLOGICAL ORGAN 
1.5.1 Liver anatomy and cell composition 
The liver is an organ important for numerous physiological processes including glucose, 
lipid, and protein metabolism, immune system support as well as degradation of toxic or 
waste products (117, 118). The liver lobules are the micro-anatomical units of the liver. 
Hexagonal in shape, they consist of chords of hepatocytes radiating from portal triads, which 
consists of the hepatic artery, portal vein and bile ducts, and converge to a central vein 
(Figure 4). The liver has a dual blood supply with oxygen-rich blood from the hepatic artery 
that mixes with nutrient-rich blood from the portal vein (117-119).  
The structural organization of the liver is of great importance for its immune function. The 
liver is highly vascularized, with blood that passes through a network of sinusoids carrying 
approximately 108 lymphocytes per day (119). Minimal increase in venous pressure and a 
small diameter of the sinusoids facilitate prolonged contact between lymphocytes and APCs 
as well as lymphocyte extravasation. Furthermore, the permeable fenestrated monolayer of 
liver sinusoidal endothelial cells (LSECs), which lack a basement membrane facilitates direct 
access to the space of Dissé, where hepatic stellate cells (HSCs) reside, and to the underlying 
hepatocytes (Figure 4) (119-121).  
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Hepatocytes constitute about two third of all hepatic cells and are together with 
cholangiocytes the main parenchymal cells of the liver (117, 119). LSECs account for the 
majority of non-parenchymal cells and have the capacity to induce T cell immunity locally by 
their APC-features: receptor-mediated endocytosis/phagocytosis, antigen processing, antigen 
presentation via MHC class I and II, and the expression of co-stimulatory molecules. Kupffer 
cells (KCs) are liver-resident macrophages and account for about 20% of non-parenchymal 
cells. Numerous KCs line the sinusoidal vessels, are highly phagocytic and play a role in 
clearing the blood of microorganisms and debris that enter the liver via the portal circulation 
(117, 119).  
In the liver, the immune cell composition differs from that in peripheral blood. NK cells are 
enriched and comprise 30%-50% of all human hepatic lymphocytes. Compared to peripheral 
blood, the frequency of CD56bright NK cells is increased in the liver (122, 123). Similarly, 
unconventional T cells, such as gd T cells and MAIT cells are enriched. In the conventional T 
cell compartment, CD8+ T cells outnumber CD4+ T cells, and the frequency of effector and 
memory T cells is higher than in peripheral blood (119, 121). B cells reside in small numbers 
in the healthy liver. Recent evidence suggests that intrahepatic follicle-like structures similar 
to those of lymph nodes exist for B cell priming and maturation (124). Notably, IgA 
producing plasma cells lining the biliary epithelium may contribute to the protection of bile 
ducts from intestinal pathogens (125). Unique mechanisms in the liver ensure its tolerogenic 
properties, but also contribute to immune responses as described below. 
 
Figure 4: The liver as immunological organ. Blood passes through sinusoids from where 
lymphocytes can directly interact with hepatocytes via the permeable fenestrated monolayer 
of LSECs. Adapted from Racanelli and Rehermann (119). 
1.5.2 Liver immunology at steady-state 
The immunological environment in the liver is unique in that high non-self-antigen exposure 
from nutrients or the microbiota does not result in inflammation, a phenomenon known as 
tolerance. This is essential for direct multiple interactions between gut and liver (“gut-liver 
axis”) whereby the liver gets continuously exposed to gut-derived compounds via the portal 
circulation including LPS (121, 126-128). Immune cells are important for maintaining liver 
homeostasis, but also represent key players in the initiation of liver diseases by responding to 
hepatic injury (119, 127, 128). Liver-resident APCs (KCs, LSECs, and DCs) line the 
capillary system and act as primary sensors, presenting antigens and producing cytokines and 
chemokines (119, 121, 129). Under homeostatic conditions, they contribute to the tolerogenic 
environment through various mechanisms. These include the production of anti-inflammatory 
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mediators (IL-10, TGF-b, arginase, prostaglandin E2), expression of indoleamine 2,3-
dioxygenase and the T cell-inhibitory molecules programmed cell death 1 ligand 1 (PD-L1) 
and cytotoxic T lymphocyte-associated molecule-4 (CTLA-4), as well as through the 
induction of Treg cells (117, 127). Alternative APCs, such as HSCs and hepatocytes, can also 
induce Treg cells or prime CD8+ T cells. This priming however, results in limited 
proliferation and clonal deletion. Alternatively, T cell apoptosis can be induced by 
hepatocytes via Fas and TNF (127). 
1.5.3 Breaking tolerance – liver inflammation 
During infection or tissue damage, rapid immune responses need to be initiated. While 
PAMPs are important to detect infections, alarmins and damage-associated molecular 
patterns (DAMPs) classically activate the immune system upon sterile tissue injury. For 
example, injured hepatocytes secrete IL-33, which stimulates Th2 responses eventually 
promoting fibrosis or the release of the high mobility group protein B1. Also, free cholesterol, 
oxidized lipids, extracellular ATP, bile acids outside the biliary tree, and uric acid act as 
irritants. This triggers the production of pro-inflammatory mediators, such as inflammatory 
cytokines, including IL-1 and IL-18, chemokines (CXCL1, CXCL9-11, CCL2, CCL5), 
growth factors (G-CSF, GM-CSF), and adhesion molecules mediating and cellular diapedesis 
into tissue (121, 128). Besides classical immune cells, cholangiocytes are immunologically 
active cells, express TLRs, and can act as APC. They have the capacity to secrete pro- and 
anti-inflammatory cytokines (IL-1b, IL-6, TNF, IFNg, TGFb), chemokines (IL-8, CCL2, 
CCL25, CX3CR1) and express adhesion molecules (ICAM-1, CD40). Thereby, 
cholangiocytes actively contribute to immune-regulation and liver pathogenesis (130, 131). 
Cellular infiltrates consist of neutrophils, macrophages, T cells, and DCs that all participate in 
the inflammatory response (128). KCs are important players during liver inflammation. They 
produce oxygen and nitrogen radicals as well as TNF, IL-1b, IL-12, and IL-18 (121). Kupffer 
cells also possess pro-fibrotic mechanisms, such as HSC activation leading to extracellular 
matrix deposition, but also participate in different processes after liver injury (121). The pro-
inflammatory cytokine milieu as well as NCR ligands expressed by stressed cells activate NK 
cells that may contribute to liver damage and/or produce cytokines, chemokines, and growth 
factors, thereby also acting as regulatory cells. For example, NK cells can be activated by IL-
18 and produce varying amounts of IFNg, contributing to antiviral, antifibrotic, and antitumor 
effects. IFNg release is however, modulated by the simultaneous production of IL-10, setting 
a baseline for pro-inflammatory immune responses (129). NK cells also indirectly regulate 
fibrosis by killing HSCs (121, 123). DCs in the liver are mainly located in the portal tracts. 
Hepatic DCs exhibit predominantly immunoregulatory rather than immunogenic functions. 
However, during inflammation, they switch to an immunogenic state and are found in portal 
tract associated lymphoid tissues (PALT), which can serve as priming sites for liver-
infiltrating T cells (121). Interestingly, in mouse models of hepatitis B virus (HBV) infection, 
it was shown that T cells directly interact with hepatocytes via protrusion through endothelial 
fenestrae. This occurred in a diapedesis-independent manner by adhering to platelet 
aggregates in sinusoids (120). However, in liver infections, CD8+ T cells show features of 
exhaustion, resulting in a dysfunctional immune response that may also be caused by the lack 
of CD4+ T cell help (121, 127). 
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In summary, the liver creates a unique tolerogenic environment that ensures liver integrity 
despite continuous exposure to antigens from the gut. Multiple cell types contribute to set the 
threshold for the engagement of immune defenses in order to balance an inflammatory state 
and immunopathology causing liver damage. 
1.6 LYMPHOCYTES IN HUMAN LIVER DISEASES AND VIRAL INFECTIONS 
1.6.1 Dengue fever 
Dengue virus (DENV) causes a major threat to global health and not only has spread wider 
geographically, but also increased in numbers of infections (132, 133). DENV is transmitted 
by Aedes mosquitos in tropical and subtropical regions of the world and belongs to the genus 
Flavivirus (Flaviviridae family) with four different serotypes (DENV1-DENV4). Other 
members of that genus are West-Nile virus, Tick-borne encephalitis virus (TBEV), Yellow 
fever virus (YFV), Japanese encephalitis virus, and Zika virus (134, 135). DENV consists of 
an enveloped spherical particle with a positive-sense, single-stranded RNA genome encoding 
three structural (capsid (C), precursor membrane (prM) and envelope (E)) and seven non-
structural (NS1, NS2A, NS2B, NS3, NS4A, NS4B, NS5) proteins. E and prM/M are part of 
the glycoprotein shell with the E protein being important for binding and entry (135). To 
date, no single receptor is yet defined to be required for viral entry, but some receptors have 
been suggested to play a role, for example heparin sulfate, DC-specific ICAM3-grabbing 
non-integrin, heat shock protein 70kDa, and mannose receptor (136). Upon receptor-
mediated endocytosis and pH-mediated fusion of the viral and the endosomal membrane, the 
nucleocapsid is released into the cytoplasm. The viral RNA is translated at the endoplasmic 
reticulum (ER) into a single polyprotein that is subsequently processed by proteases. RNA 
synthesis begins and the new RNA is packed in C protein, buds into the ER, followed by 
transportation through the trans-Golgi network, where prM is cleaved off and mature viral 
particles are released from the cell (135). 
An infection with DENV results in the clinical syndrome known as dengue fever (DF). DF 
affects up to 390 million individuals annually thereby causing a serious health threat and 
economic burden to affected areas (132). The clinical picture varies from mild to severe 
forms of DF, with severe forms being dengue hemorrhagic fever (DHF) and dengue shock 
syndrome (DSS), which may lead to fatal outcomes (132). Most patients recover from an 
either asymptomatic or self-limiting non-severe clinical course with symptoms during an 
acute febrile phase of 3-8 days, accompanied by skin rashes, muscle and joint pain, and 
headache. Some patients have symptoms affecting gut and liver, including nausea, vomiting, 
and eventually liver enlargement, whereas the more severe forms are characterized by plasma 
leakage with or without hemorrhage during the critical phase. Factors influencing the 
response to infection include immune status, viral serotype, host genetics, and age (137). At 
present, no effective anti-viral agents exist. However, supportive care by intravenous 
rehydration reduces the fatality enormously (138).  
Interestingly, the immune system has been suggested to play a role in dengue pathogenesis. 
The infection starts locally in the skin where resident innate immune cells, including 
macrophages, Langerhans cells and mast cells reside. Langerhans cells migrate to draining 
lymph nodes from where the infection spreads and becomes systemic (139). Mast cells 
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contribute with the release of pro-inflammatory mediators, such as TNF that up-regulates E-
cadherin on endothelial cells and secrete chemokines (134, 140). During primary infection 
with DENV, a serotype-specific adaptive immune response is mounted, whereas in secondary 
infection with a heterologous serotype cross-reactive plasmablasts and memory T cells can be 
found (134). These secondary infections with a different serotype have been claimed to be a 
risk factor for more disease due to antibody-dependent enhancement (ADE), a mechanism by 
which the infection rate is increased by binding of virus in complex with non-neutralizing 
antibodies to Fc receptors promoting viral uptake. This in turn has been suggested to result in 
increased secretion of pro-inflammatory cytokines and chemokines (135, 139). This so called 
“cytokine storm”, induced by increased infection rate and/or cross-reactive weak-affinity T 
cells, includes increased levels of TNF, IFNg, CXCR8, CXCR9-11, CCL5, vascular 
endothelial growth factor (VEGF), and IL-10 and is associated with the peak in symptoms 
after the incubation period of 4-7 days. During this phase, viral loads are rapidly decreasing, 
suggesting immune-mediated viral control. Disease severity correlates with the magnitude of 
the T cell response (135). Interestingly, Rivino et al. showed that T cells home to the skin 
during the acute phase of the infection (141). Thus, DENV-induced immune responses can 
both be protective, resulting in efficient control of the infection and can contribute to 
immunopathology, increasing disease severity. 
1.6.2 NK cells in acute virus infections  
NK cells are important in the response to viral infections (142). This has been demonstrated 
in mouse models for a diverse range of acute infections, including cytomegalovirus (CMV), 
herpes simplex virus (HSV)-1, influenza virus, and poxvirus (14, 142). In humans, their 
importance has become clearer in rare NK cell deficiencies that result in high susceptibility to 
herpesvirus infections including HSV, varicella zoster, and CMV (143, 144). Nevertheless, 
most studies that have led to advanced knowledge of NK cell responses in viral infections 
were conducted using murine systems (145). More recent research has revealed insights into 
NK cell responses during acute viral infections in a human setting (146-152). Numerous 
studies demonstrated that NK cells respond during natural viral infections, including 
hantavirus (146), TBEV (147), chikungunya virus (148), DENV (153), CMV (151), Epstein-
Barr virus (EBV) (152), hepatitis C virus (HCV) (154), and human immune deficiency virus 
(HIV)-1 (149). However, due to difficulties in collecting human samples in a controlled way 
before early acute infection has passed, only few studies have longitudinally followed NK 
cell responses during the acute phase and beyond. In DENV infection, NK cell numbers are 
increased and activation markers are upregulated in patients with DF compared to patients 
with DHF (155, 156). In other flavivirus infections, such as in TBEV or after YFV 
vaccination, a similar activation of NK cells has been reported (147, 157). Furthermore, 
progress has been made during the recent years, characterizing receptor-ligand pairs and 
cytokine-mediated effects on NK cells during viral infections as well as infection-induced 
changes in the NK cell receptor repertoire (36). Besides NK cell activation seemingly driven 
by cytokine priming (157), previous studies have shown that certain acute infections result in 
expansion of distinct NK cell populations exhibiting a terminally differentiated phenotype 
(146, 148, 151, 158). These expansions are most likely driven by underlying human 
cytomegalovirus (HCMV) infection (146, 159). This phenomenon does occur in some, but 
not other infections, such HSV-2 or EBV infections (160, 161). Sun et al. described a clonal-
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like NK cell expansion, contraction, and persistence upon murine cytomegalovirus (MCMV) 
infection, leaving a population with enhanced responses upon re-challenge, so called memory 
or adaptive-like NK cells (162). In humans, a population of adaptive-like NK cells highly 
express NKG2C, CD57, and DNAM-1, are skewed towards an increased expression of self-
KIRs, and are low in NKG2A and NCR expression (158, 163). Moreover, hapten-specific as 
well as cytokine-induced (IL-12, IL-15, IL-18) memory cells were described with the latter 
ones expressing high levels of CD25, perforin, granzymes and IFNg (164). Other receptors in 
direct NK cell receptor recognition of virus induced-ligands have been shown to be 
important, for example in influenza (NKp46) and in DENV infection (NKp44) (35, 165). 
Notably, epidemiologic studies have linked KIR-HLA repertoires to disease susceptibility in 
anti-viral immune response and therefore impact disease outcome. Such associations were 
shown in HCV with KIR2DL3 and HLA C1 being associated with self-resolving HCV, and 
in HIV showing that the KIR3DSL-HLA-B Bw80I interaction is beneficial for better HIV-1 
control (166). Intriguingly, specific recognition of viral peptides has recently been shown to 
be a feature of NK cells binding HCMV-derived peptides presented by HLA-E or by HLA-C, 
activating NKG2C and KIR2DS1, respectively (167). Additionally, KIR2DS2 recognizes 
HLA-C-binding peptides from the NS3 helicase, which are highly conserved in Flaviviruses 
including HCV and DENV (168). 
Table 2: Homing receptor-ligand pairs in infectious and inflammatory diseases 
Receptor Main ligand Tissue Disease Human/mouse Source 
CCR5 CCL3 lung Klebsiella pnemoniae mouse (169) 
  vagina 
Genital 
HSV-2 mouse (170) 
  liver/spleen Toxoplasma mouse (171) 
CCR5 CCL3, CCL4 liver MCMV mouse (172) 
   HIV human (173) 
CCR2 CCL2 lung Invasive aspergillosis mouse (174) 
CCR4 CCL2 (CCL4, CCL5) lung 
Invasive 
aspergillosis mouse (174) 
CXCR3 CXCL9-11 brain Coronavirus mouse (175) 
a4ß7 MadCAM-1 gut SIV/HIV macaques/humans (176) 
      
CCR5 CCL3 liver  human (177) 
  joints RA human (178, 179) 
  skin Psoriasis human (91, 180) 
CXCR6 CXCL16 liver  human (177) 
CX3CR1 CX3CL1 CNS Multiple sclerosis human (181) 
CXCR3 CXCL9-11 skin Psoriasis human (91, 180) 
CCR8 CCL1 skin Psoriasis human (180) 
CLA E-selectin skin  human (182) 
CCR7 CCL19, CCL21 lymph nodes   (183) 
CCR9 CCL25 gut  human (184) 
CCR6 CCL20 skin  human (91, 180) 
CCR10 CCL27, CCL28 skin  human 
(180, 182, 
185) 
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In addition to cellular responsiveness and functional capacity, viral control requires 
recruitment of activated immune cells to the site of infection (142). Distinct chemokine-
chemokine receptor pairs are important for NK cell recruitment to lymphoid and non-
lymphoid organs during inflammation and infection. However, NK cell homing in viral 
infections has yet mainly been addressed in mice (Table 2). 
Hence, little is known about temporal dynamics with regard to the NK cell response and 
trafficking to peripheral organs during viral infections in humans, including DENV infection. 
1.6.3 Chronic Hepatitis B 
Viral hepatitis is one of the leading causes for death worldwide with approximatively 250 
million people being chronically infected with HBV (186). HBV is a hepatotropic, small, 
enveloped DNA virus that belongs to the Hepadnaviridae family. By itself, the virus is non-
cytopathic but eventually leads to progressive liver fibrosis, cirrhosis, and an increased risk of 
liver cancer, in particular hepatocellular carcinoma (187, 188). Nine genotypes (A-I) and 
several sub-genotypes have been identified with differences in their geographic distribution 
(187). The most common transmission routes are mother-to-child transmission, sexual 
transmission, as well as needle sharing. HBV infections can be acute or chronic with low 
rates of chronicity in adults (5%), but very high persistence rates in neonatal infections (188). 
Chronic HBV (CHB) infection can be classified into different phases that are characterized 
by presence of varying levels of HBV DNA, hepatitis B e antigen (HBeAg), hepatitis B s 
antigen (HBsAg), and their respective antibodies in circulation. Some of these phases are 
associated with liver damage, which is measurable by alanine aminotransferase (ALT) and 
fibrosis markers (187). 
The viruses’ DNA encodes seven proteins: HBcAg (core antigen, viral capsid), HBeAg 
(secreted splice variant of the HBc, indicates active replication of HBV), HBV Pol 
(polymerase with reverse transcriptase activity), PreS1/PreS2, HBsAg (large, medium, small 
surface glycoproteins), and HBx (x antigen, initiation of transcription). Upon sodium 
taurocholate co-transporting polypeptide (NTCP)-mediated infection (189, 190), the 
nucleocapsid is transported to the nucleus where the HBV DNA is converted into covalently 
closed circular DNA (cccDNA). It serves as a template for transcription, which is followed 
by translation of different viral proteins. Pre-genomic RNA is reverse transcribed by the RNA 
polymerase into new HBV DNA. Nucleocapsids containing HBV DNA are either recycled to 
maintain the cccDNA reservoir or enveloped and secreted together with genome-free subviral 
particles, which are non-infectious, but still being produced when reverse transcription is 
blocked (191) (Figure 5). Viral genome integration of HBV occurs randomly and may lead 
to hepatocyte transformation (187). 
The overall goal of antiviral HBV therapy is to improve survival and quality of life (187, 
192). To date, treatment with pegylated interferon alfa (pegIFNa) and nucleos(t)ide 
analogues (NA) are the two main therapies available (187). pegIFNa elicits both anti-viral 
and immunomodulatory effects (193, 194) while NAs efficiently suppress HBV replication 
by inhibiting the viral RNA polymerase (187). NAs are well-tolerated and have a beneficial 
effect on disease progression (187). Thus, NAs are most commonly used nowadays. The 
ultimate goal of treatment is HBsAg loss with or without HBs-seroconversion (192, 195), 
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indicating immune control of HBV and suppression of viral replication and protein 
production. However, this goal is rarely achieved with current treatment options. HBsAg loss 
and undetectable HBV DNA, also termed functional cure, does not include complete removal 
of cccDNA or integrated DNA, but allows to safely stop anti-viral therapy (187, 195). NA 
treatment can be long-term, because the rate of HBsAg decline is low (196). In contrast, 
treatment with pegIFNa is given over a defined period of time with higher response rates 
than in NA treatment. Its goal is sustained off-treatment response with low HBV DNA levels 
and normal ALT levels, a marker used to determine liver injury. However, side effects during 
pegIFNa therapy are severe. Thus, an important clinical need is to optimize strategies to 
shorten the duration of antiviral therapies by augmenting HBsAg loss (187, 195). As such, a 
variety of studies evaluated the feasibility of stopping NA treatment in CHB patients (197-
201). Despite the recurrence of HBV DNA, treatment cessation is safe and was recently 
introduced into the European Association for the Study of the Liver (EASL) guidelines (187). 
NA treatment termination is recommended for well-selected HBeAg-negative patients. 
Hadziyannis et al. highlighted the importance of this new concept by showing HBsAg loss at 
long-term follow up in a third of patients after NA cessation (202). In most patients, an 
increased viral load was followed by ALT flares (202). These results correspond with a report 
by Siederdissen et al., who could also show an induction of inflammatory/anti-viral cytokines 
upon NA cessation (203). Still, the underlying immunological correlates of the observed 
events after NA cessation remain elusive. 
  
Figure 5: HBV structure and replication. HBV is an enveloped DNA virus. During viral 
replication cccDNA resides in the nucleus of hepatocytes and serves as template for 
transcription. NAs block the viral RNA polymerase and thereby block the release of 
infectious virions, but not subviral particles. Adapted from Yan et al. (189) and Seeger et al. 
(191). 
Studies addressing early immune responses during natural HBV infection in humans are rare 
due to an asymptomatic incubation period of HBV infection (150, 204). For this reason, 
model systems, such as chimpanzees, have shown that HBV does not activate interferon-
stimulated genes during acute infection (204). This is in line with a diminished early 
production of type I IFN in humans (150). Therefore, HBV has been suggested to be a 
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“stealth virus” (204). Moreover, HBV seems to exert several immunoregulatory mechanisms 
that in turn may contribute to viral persistence (205-208). In humans, acute infection was 
accompanied by IL-10 production and coincided with temporally impaired NK cell and T cell 
functionality (150). An impairment of early immunity is challenged by HBV model systems, 
showing non-cytolytic clearance of the virus (209, 210) as well as another report in humans 
showing early activation of functional NK cells (211). Generally, acute infection is described 
as a self-limiting inflammatory disease with potent immune responses followed by viral 
clearance (211, 212). Both innate and adaptive immune responses are efficient and are 
characterized by activated NK cells (211), robust T cell responses (213), as well as by 
neutralizing antibodies produced by B cells (214). The interplay between HBV replication 
and the host immune responses largely affects the outcome of CHB infection. 
1.6.4 NK cells in chronic hepatitis B 
The progression from acute to CHB results from ineffective attempts by the host immune 
response to clear virus (215). NK cells have been studied in the context of CHB (216). 
Several reports indicate an increase in CD56bright NK cells in CHB (216-220). A recent meta-
analysis revealed that NK cells express higher levels of the activating receptors NKp46, 
NKp30, NKG2C and NKG2D (216), whereas Tjwa and collegues reported an increase in 
NKG2A and downregulation of CD16 and NKp30 (221). Furthermore, multiple studies have 
shown functional dichotomy in the NK cell compartment with retained cytolytic activity but 
suppressed cytokine production (217, 218, 222, 223). Selective defects of NK cell function 
may be partly due to the immunosuppressive cytokine environment created through high 
levels of IL-10 and TGF-b (218). Studies using transgenic mouse models have shown that 
liver damage is induced by immunological mechanisms rather than the virus itself (224). 
Although virus-specific CD8+ T cells have been identified as the main effectors for 
controlling viral replication, in chronic infection these cells are exhausted and functionally 
impaired. This suggests that hepatocyte injury might be caused by non-antigen specific 
immune cells infiltrating the liver (225). This indicates a role for NK cells in contributing to 
viral persistence and liver pathology (213). In this regard, it is interesting to note that the NK 
cell frequency has been shown to be positively correlated with disease severity (223). In 
addition to retained cytotoxicity, activated TRAIL-expressing NK cells have been reported to 
accumulate in CHB livers (219). There, TRAIL and TRAIL receptor expression on 
hepatocytes are associated with elevated IFNa and IL-8 levels, respectively (219). 
Additionally, an increase in TRAIL-expression on CD56bright NK cells correlated with liver 
damage (223). Therefore, TRAIL-mediated death of hepatocytes was suggested to contribute 
to liver inflammation (219, 223, 226). This is in line with a study by Zhang et al. showing 
more pronounced cytolytic activity of hepatic NK cells as compared to NK cells from 
peripheral blood (227), which was associated with liver damage in HBeAg positive CHB 
patients (227, 228). Recently, NK cells were shown to regulate immunopathology by acting 
as rheostats (229) by cytolytical elimination of HBV-specific T cells (223, 226). 
The HBV DNA level-decline upon NA treatment has been shown to modulate the peripheral 
blood NK cell phenotype (217, 221). However, contradictory results were reported for NK 
cell activation and cytokine-producing capacity as either unaffected (217) or restored (221) 
upon NA treatment. Yet another study revealed that long-term NA treatment-induced viral 
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suppression did not modulate frequency, phenotype, and activation of intrahepatic NK cells 
(230). In contrast to NA treatment, pegIFNa has been reported to induce an expansion of 
activated TRAIL-expressing CD56bright NK cells coinciding with IL-15 production (231). 
This was in line with the strong immunomodulatory effect observed in combination therapy 
of NAs and pegIFNa with higher frequency of TRAIL-expressing CD56bright NK cells and 
increased NK cell functionality in responders compared to non-responders (232-234). 
Without achieving HBsAg loss, however, add-on therapy is questionable. Instead, it has 
recently been suggested that a fraction of HBeAg-negative non-cirrhotic patients with time 
experience HBsAg loss after the initial viral rebound and flare of hepatitis occurring 
following NA interruption (202, 203). However, correlates explaining the virological and 
cellular events are lacking. 
1.6.5 T cells in chronic hepatitis B 
In contrast to self-limiting acute HBV infections, CHB is characterized by qualitatively and 
quantitatively impaired HBV-specific T cell responses (235-237). T cell dysfunctionality was 
shown to be associated to viral load (235, 237), but may also be caused by the lack of CD4+ 
T cell help, increased Treg cells, immunosuppressive cytokines, and/or nutrient deprivation 
(238). In contrast to acute HBV infection, HBV-specific T cells are rarely detected in CHB 
(235). In this regard, Peppa and colleagues could show that TRAIL-expressing NK cells 
mediate deletion of TRAIL-R2 expressing HBV-specific T cells during hepatic flares (226), 
potentially contributing to the lack of HBV-specific T cells. Nevertheless, HBV-specific T 
cells are believed to be essential for viral clearance (235) and are more associated with viral 
control than liver damage (225). T cell exhaustion is believed to be driven by the chronic 
exposure to antigens and is accompanied by a hierarchical loss of anti-viral T cell functions, 
starting with the loss of cytotoxicity and IL-2 production, which is followed by the reduction 
of TNF and IFNg and finally T cell deletion (239). Moreover, exhausted T cells lose their 
proliferative capacity and express a variety of inhibitory molecules (240), also termed 
“exhaustion markers”, such as PD-1 (235), CTLA-4 (241), and TIM-3 (242). As such, PD-1 
gets phosphorylated upon ligand binding (PDL-1, PDL-2), which leads to the recruitment of 
the tyrosine phosphatase Shp2 that dephosphorylates CD28 or the TCR complex, thereby 
attenuating TCR/CD28 signaling (238). Blocking these inhibitory receptors, a strategy known 
as checkpoint blockade, is therefore considered to be one strategy to potentially boost T cell 
functionality in CHB (235, 241, 242). Several inhibitory receptors can be co-expressed on 
exhausted cells and show a synergistic effect when blocked simultaneously (240). 
Additionally, recent evidence suggests that transcriptional and metabolic derangements 
contribute to T cell exhaustion (240). Paley and colleagues described a subset of T-betdim 
Eomeshi PD-1hi T cells as exhausted with limited proliferative capacity, weaker cytokine 
production, and poor response to PD-L1 pathway blockade driven by T cell downregulation 
upon persistent antigen exposure (243). Indeed, a decline of T-bet (246) as well as TCF-1 
(247) has been associated with dysfunctional HBV-specific T cells in CHB, whereas high T-
bet expression is strongly associated with spontaneous virus control (246). T-bet and Eomes 
have also been shown to be associated to exhausted T cells in other viral infections, including 
HIV (244). In addition, exhausted T cells can co-express other inhibitory receptors, such as 
KLRG1, while KLRG1 and CD57 are generally described markers of terminal differentiation 
and/or senescence (245). Furthermore, metabolic changes causing bioenergetic deficiencies 
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(245) have been described to be an early driver of T cell exhaustion being more prevalent in 
the PD-1hi subset, suggesting that the manipulation of T metabolism may be a complement to 
checkpoint blockade (248). To what extent HBV-specific T cell functionality is affected in 
the liver in still unknown. In this regard, Pallet et al. reported that TRM cells reside in the liver 
and are expanded in patients with partial or complete immune control (115). 
Treatment with pegIFNa and NAs results in variable outcomes in relation to HBV-specifc T 
cell responses. HBV-specific CD8+ T cells were shown not to be affected (249) or lost (231) 
upon PegIFNa therapy without a restoration of T cells dysfunctionality (231, 249). As 
opposed to treatment with pegIFNa, reduced viral loads upon NA therapy partially restored 
HBV-specific T cell responses in vitro (250, 251), particularly in patients experiencing 
HBsAg loss (252). Accumulating evidence suggests that stopping NA may lead to HBsAg 
loss in a selective group of patients and is commonly associated with hepatic flares (202). 
Rivino et al. demonstrated that patients with sustained HBV DNA control upon NA 
discontinuation had increased frequencies of core and polymerase HBV-specific T cells 
before the treatment discontinuation. These functional HBV-specific T cells are enriched in 
the PD-1+ population and were suggested as an immunological biomarker for safe therapy 
discontinuation (253). However, whether improved functionality of HBV-specific T cells 
contributes to HBsAg loss at long-term follow up remains elusive. 
1.6.6 Primary sclerosing cholangitis (PSC) 
Primary sclerosing cholangitis (PSC) is a rare cholestatic liver disease, which is characterised 
by inflammation and fibrotic scarring of intra- and extrahepatic bile ducts. The hallmark of 
PSC are biliary strictures and recurrent bacterial cholangitis, which ultimately leads to biliary 
cirrhosis and end-stage liver disease (254). 60%-80% of PSC patients simultaneously have 
IBD, in particular ulcerative colitis (UC). Both men and women at any age can be affected, 
but the classical PSC patient is male with a median age of 30-40 years at disease onset. PSC 
can be asymptomatic without being diagnosed early or patients may have symptoms such as 
itching, abdominal pain, jaundice, fevers and fatigue. For diagnostics, serum liver tests 
assessing for levels of alkaline phosphatase (ALP) and magnetic resonance 
cholangiopancreatography are used. PSC patients have an increased risk to develop 
cholangiocarcinoma (CCA) and colon cancer in the presence of IBD. There is no treatment 
that can halt disease progression. To date, liver transplantation is the only treatment option 
available (126, 254-256). Nevertheless, endoscopic cholangiopancreatography (ERCP) is 
used to treat strictures and obstruction of the large bile ducts to relieve symptoms such as 
itch, jaundice, and cholangitis, as well as for evaluating the characteristics of the strictures 
and to rule out malignancy (254). There is a need for effective treatments, yet the 
development of these has been impeded by a poor understanding of the pathogenesis and 
pathophysiology of PSC.  
Several factors have been considered to contribute to the disease (254, 256). The involvement 
of a genetic component is supported by the fact that first-degree relatives of PSC patients 
have an increased risk for PSC development (257). Furthermore, genome wide association 
studies indicate a variety of susceptibility genes being involved in the development in PSC, 
identifying similarities to other autoimmune diseases, such coeliac disease and rheumatoid 
arthritis. These genes associate with the immune system, but also with other pathways, such 
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as apoptosis, cell growth/death, autophagy, and metabolism. The exact role of the majority of 
these genes is unclear and needs be further explored. Environmental triggers account for the 
total risk, with diet and smoking as factors of influence (126). The role of the gut-liver axis 
has been emphasized along with the “leaky gut hypothesis”, suggesting that bacterial 
translocation in the gut increases the presence of bacterial antigens in the portal zone of the 
liver, thereby triggering biliary inflammation (254, 256). The presence of bacterial products 
and genetic associations indicate an involvement of an immune component in the PSC 
pathogenesis. For example, bacterial antigens present in the gut may trigger immune cell 
infiltration via PAMP recognition (innate) or T cell homing to the liver due to an overlap in 
endothelial adhesion molecules in both compartments (adaptive), highlighting the importance 
of the cross-talk with activated cholangiocytes (256). Furthermore, autoantibodies with 
unknown pathologic significance, for example anti-neutrophil cytoplasmic antibodies, are 
frequently detected in PSC. Both IgG and IgA classes have been found and may reflect B cell 
responses to gut derived antigen following sustained inflammation. Autoantibodies in PSC 
may also target biliary epithelial cells (BECs) directly (256, 258). Toxic bile injury caused by 
defects in mechanisms protecting against bile duct toxicity, for example the presence of 
bicarbonate (HCO3-) layer (“umbrella”), and disturbance in bile homeostasis have been 
suggested to contribute to PSC development. Interestingly, a reduction in microbial diversity 
has been observed, most likely also impacting bile homeostasis (254, 256, 259). Ultimately, 
HSCs and myofibroblast activation is involved in fibrosis development and the eventual 
progression to other PSC-related liver conditions, such as stricture formation, cirrhosis, and 
CCA (256). 
1.6.7 The biliary immune system in PSC 
The immune system is believed to play an important role in PSC pathogenesis (126, 256, 
258). However, limited data are available that contribute to the understanding of the 
immunopathology in PSC that is believed to be a multi-step process (258). Histopathological 
findings show mixed immune cell infiltrates in portal areas and around bile ducts (258), but 
very little knowledge about the biliary immune system is currently available. Accumulating 
evidence from early studies, mainly investigating mononuclear cells in bile ducts using 
immunohistochemistry, suggest CD8+ memory T cells to be the dominant population among 
IELs (260-262). Furthermore, macrophages and neutrophils reside closely to bile ducts (256). 
More recent genetic studies support an involvement of the immune system in the PSC 
pathogenesis. The strongest associations were found in the HLA complex, indicating an 
important role of the adaptive immune system. Nevertheless, both the innate and the adaptive 
immune system appear to be affected. Examples are PRDX5, TGR5, and PSMG1 (LPS 
response in humans), NFKB1, REL, PRKD2/CB (cytokine production, proliferation), 
TNFRSF14 (TNF signaling pathway), IL2RA (IL-2 signaling pathway), PRKD2 (effector 
cytokine production), SOCS1 and SH2B3 (regulation of cytokine production), CXCR1, 
CXCR2, and CCL20 (leukocyte homing), and CD28, CD226, CTLA4 (co-
stimulatory/inhibitory receptors) (126). In summary, various susceptibility genes may impact 
immune responses, particularly genes involved in T cell development and differentiation, 
activation and proliferation, migration, and apoptosis (126). Further studies need to shed light 
on their function, especially their role in immune cell cholangiocyte cross-talk. In that regard, 
Liaskou et al. showed that higher frequencies of CD28- T cells were present in livers of PSC 
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patients than in patients with primary biliary cirrhosis or alcoholic steatohepatitis (263). 
These cells localized around bile ducts and were described as being equipped with cytolytic 
molecules and capable of producing IFNg and TNF, thereby contributing to BEC activation 
(263). Even though CD4+ CD28- T cell have been linked to autoimmunity, the lack of CD28 
generally identifies T cells that are antigen experienced and highly differentiated exhibiting a 
variety of different functions (264). The existence of disease-specific TCR repertoires may 
suggest the presence of disease-associated antigens. Despite a high T cell diversity in PSC, 
disease-associated clonotypes were identified and have therefore been suggested to be 
evidence for antigen-driven clonal expansions (265). On the other hand, a specific cytokine 
milieu, for example IL-17, has been shown to drive inflammation and fibrosis. Interestingly, 
Th17 as well as MAIT cells, both being IL-17 producers, are important for the defense 
against bacteria and fungi that are present in a majority of bile fluid samples of PSC patients. 
Upon pathogen stimulation, more CD4+ T cells exhibit a Th1/Th17 profile in PSC patients 
compared to controls (266), whereas the Treg compartment appears to be dysregulated in 
terms of Treg frequency and function (267). Of note, cholangiocytes express increased levels 
of TLRs in PSC and therefore have the potential to detect PAMPs that can activate 
cholangiocytes causing proliferation, secretion of pro-fibrotic, and pro-inflammatory 
mediators (131, 268, 269). This aids tissue repair, but also promotes Th17 differentiation and 
the recruitment and localization of immune cells, such as T cells, expressing CXCR6, CCR6, 
and CCR10 binding to CXCL16, CCL20, and CCL28, respectively (131, 268-270). In that 
context, Eksteen et al. demonstrated that T cells primed for gut homing were recruited to the 
liver due to the aberrant expression of CCL25 and mucosal addressin cell adhesion molecule 
(MadCAM)-1 in PSC, binding to CCR9 and a4b7, respectively (271). Once in the liver, 
cholangiocyte-T cell interactions are augmented via the upregulation of adhesion molecules 
and antigen presentation by increased expression of MHC class I and II by activated 
cholangiocytes (131). In addition, and in line with antigen presentation to conventional T 
cells, BECs have the capacity to present bacterial antigens via MR1 to activate MAIT cells 
that were shown to localize in portal tracts and around bile ducts (272). In conclusion, 
accumulating evidence suggests an involvement of T cells in PSC pathogenesis. A detailed 
characterization of the biliary immune system is however missing, which is of great 
importance to understand bile duct-associated inflammatory diseases. 
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2 AIMS 
The overall aim of this thesis was to characterize lymphocytes in human diseases. In 
particular, the work was focused on NK cell responses during an acute viral infection with 
dengue virus and NK cell and T cell responses after stopping nucleos(t)ide analogue 
treatment in a chronic infection with hepatitis B virus. Moreover, the role of MAIT cells and 
tissue-resident T cells was explored in primary sclerosing cholangitis. 
 
Specific aims: 
Paper I: To study the phenotype, differentiation, and education status of NK cells and the 
impact of DENV-infection on NK cell functionality and tissue homing properties. 
 
Paper II and III: To investigate whether stopping NA therapy in a cohort of HBeAg 
negative CHB patients induces immune responses that contributes to HBsAg loss. 
Specifically, we aimed to characterize NK cell (paper II) and T cell (paper III) phenotypes, 
activation status, and functional capacity at NA treatment termination and during treatment 
interruption. 
 
Paper IV: To characterize MAIT cells in peripheral blood and to assess their presence in bile 
ducts in patients with PSC and non-PSC controls. 
 
Paper V: To characterize the biliary immune system during inflammation and in non-
inflammatory controls. Moreover, to characterize the IEL compartment in relation to immune 
composition with a particular focus on biliary-resident T cells. 
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3 METHODOLOGICAL APPROACH 
3.1 ETHICAL CONSIDERATIONS 
All studies included in this thesis were performed in accordance with ethical guidelines 
described in the Declaration of Helsinki. All patients signed a written informed consent prior 
to participating in a study. The studies included were approved by the respective regional 
ethic committees as per the following permit numbers: DSRB 2013/00209 and DCRB 
2008/00293 (paper I), 5908 (paper II and III), Dnr 2013/2285-31/3 and 2013/2084-
31/2 (paper IV and V), and 2010/678-31/3 (paper V). 
3.2 SAMPLE COLLECTION, PROCESSING AND IMMUNE CELL ISOLATION 
Peripheral blood was collected in heparin-coated vacuum tubes (paper I-V). Peripheral blood 
mononuclear cells (PBMCs) were isolated by density-gradient centrifugation using Ficoll 
Hypaque, followed by the collection of the interphase. PBMCs were directly stained or 
cryopreserved for later analysis. 
Skin blisters were induced on the forearm of DENV-infected patients and controls by 
applying a negative pressure (25-40 kPa) using a suction chamber for 2-4 hours until a 
unilocular blister was formed (273). Subsequently, the blister was covered with an adhesive 
dressing and the accumulated fluid was aspirated after 18-24 hours. The cellular content was 
pelleted and analyzed by flow cytometry (paper I). 
Liver tissue was obtained from fresh pieces of liver after resection surgery. Sinusoidal blood 
was collected by flushing the liver. Liver digestion was conducted using a three-step 
perfusion protocol with collagenase XI (Sigma). Following digestion, the liver was cut into 
small pieces and subsequently filtered. The cells were then pelleted and washed twice to 
remove remaining collagenase. After hepatocyte removal by centrifugation, mononuclear 
cells were isolated by density-gradient centrifugation from the remaining supernatant (paper 
V). 
Biliary brush samples were collected during ERCP, followed by an enzymatic digestion in 
RPMI medium supplemented with collagenase II (Sigma-Aldrich) and DNase (Roche). After 
the digestion was stopped, the cellular components were pelleted, washed and subsequently 
used for flow cytometry (paper IV and V). 
3.3 MEASUREMENT OF PLASMA PROTEINS 
Plasma concentration of proteins were measured using a magnetic luminex bead assay or by 
sandwich ELISA according to the manufacturer instructions (paper I). 
3.4 KIR AND KIR-LIGAND GENOTYPING  
For KIR and KIR-ligand genotype determination, genomic DNA was isolated and used for 
PCR amplification using KIR and HLA typing kits (Olerup SSP). The genotype was 
determined according to the products that were separated by gel electrophoresis (paper I). 
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3.5 IN VITRO FUNCTIONAL ASSAYS 
The functional capacity of NK cells was assessed in vitro (paper I and II). PBMCs were 
thawed and either rested in medium or stimulated with IL-12 and IL-18 for testing NK cell 
responsiveness upon cytokine priming. To test natural cytotoxicity, target cells were added to 
the cell culture for six hours. K562 cells, a human erythroleukemia cell line, and 721.221 
cells, a human B lymphoblastoid cell line, both being deficient for HLA class I expression, 
induce potent NK cell responses by engaging multiple NK cell activating receptors, 
evaluating basal levels of NK cell responsiveness. Moreover, 721.221 cells (expressing 
CD20) were also used to determine NK cell-mediated ADCC by adding rituximab (chimeric 
monoclonal antibody against CD20) to the culture. In order to detect and quantify 
degranulation, anti-CD107a antibody was present throughout the assay. CD107a (lysosomal-
associated membrane protein-1) co-localizes with perforin in secretory lysosomes and is 
presented on the cell surface during degranulation upon membrane fusion of lysosomes with 
the cell membrane. Monensin (GolgiStop, inhibits distal Golgi function, avoiding the 
degradation of re-internalized proteins) and Brefeldin A (GolgiPlug, prevents exocytosis of 
cytokine containing vesicles) were added one hour after starting the respective assay. 
To assess functionality of HBV-specific T cells (paper III), PBMCs were thawed and 
stimulated with 15-mer HBV-specific overlapping peptide pools (core, polymerase, and 
envelop) that were also used for re-stimulation at day 10. RhIL-2 was added to the culture on 
day 4 and 8 for T cell survival and expansion. On day 10, T cells were re-stimulated and 
Brefeldin A was added to prevent cytokine secretion. T cell restoration was evaluated with 
the addition of anti-PD-L1 and MitoTempo.  
To evaluate the general (unspecific) functional capacity of T cells, cells from biliary brush 
samples and matched PBMCs were stimulated with phorbol 12-myristate-13-acetate (PMA, 
activates protein kinase C)/ionomycin (triggers calcium release) (paper V).  
The functional capacity of MAIT cells was tested using thawed PBMCs that were either 
stimulated with the combination of IL-12 and IL-18 or E. coli for 24 hours. To determine 
which responses were MR1-dependent, anti-MR1 antibody or the IgG2a isotype control was 
added at the beginning of the assay to the cultures stimulated with E. coli. Anti-CD107a 
antibody was used to detect degranulation upon both stimulations. In order to measure 
cytokine production, Monensin and Brefeldin A were added for the final 6 hours of 
stimulation (paper IV). 
3.6 FLOW CYTOMETRY 
Multicolor flow cytometry 
Extracellular and intracellular protein expression was detected using flow cytometry, a 
method that allows the binding of fluorescent dye-conjugated antibodies to their respective 
antigens on single cells in suspension. The fluorochromes get excited when they pass through 
a laser beam and emit light at a specific wavelength. The light is directed by mirrors to optical 
filters that provide spectral resolution and are placed in front of detectors. They restrict the 
wavelength range of light sensed by detectors that in turn convert it into a digital signal. In 
addition to fluorescently-labeled antibodies, we visualized biotinylated and purified 
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antibodies with fluorescent-tagged streptavidin and anti-IgM secondary antibodies, 
respectively. Dead cells were excluded using LIVE/DEAD cell stain kits. Before intracellular 
staining, cells were fixed with fixation/permeabilization buffer (eBioscience) (paper I-V) or 
Cytofix/Cytoperm kit (BD Bioscience) (paper III). Samples were acquired on a 16-
parameter 3 laser/18-parameter 4 laser BD LSR Fortessa (BD Biosciences) (paper I-V). 
Cell signaling analysis by phospho-flow 
Flow cytometry can be used for the analyses of phosphorylated proteins at a single cell level 
in phenotypically distinct populations directly ex vivo or upon different stimulations. Thus, 
this technique allows the detection of cell signaling events by using phosphor-specific 
antibodies. Stimulation was stopped with 2% formaldehyde. Cells were stained 
extracellularly, permeabilized with methanol and subsequently stained for phosphor-epitopes 
(paper I). 
Flow cytometry data analysis 
Flow cytometry data analysis was performed using FlowJo version 9.9.4. SPICE version 5.3 
(paper I-III, V) and R version 3.3.1 (paper I-V) were used for post-processing of the data. 
For data visualization and analyses, we used stochastic neighbor embedding analysis (SNE) 
that reduces a high dimensional dataset to a two-dimensional graph (274). This algorithm 
clusters cells with similar characteristics together, illustrating multivariate relationships 
between cells that otherwise may not be detectable or missed by manual gating. Furthermore, 
conventional gating introduces a bias that can be avoided by using SNE. The clustering is 
based on markers of interest and compares, using an in-house developed algorithm, two 
specific groups with substantial differences that are visualized as residual plot. These 
identified clusters can subsequently be projected onto SNE maps showing the intensity for 
each marker included in the analysis, allowing the reader to easily compare marker 
expression in the most distinguishing clusters of both groups. 
3.7 MICROSCOPY 
Immunohistochemistry 
For analysis of protein expression in liver tissue, immunohistochemistry was used. Frozen 
sections were air dried, fixed with 4% paraformaldehyde and subsequently blocked in two 
steps, one for elimination of endogenous peroxidase activity (Bloxall) and another one for 
reduction of general background staining (Innovex background buster). The sections were 
incubated with the specific primary antibody overnight. This was followed by an incubation 
with the secondary anti-mouse ImmPRESS antibody that binds to the primary antibody and is 
coupled to peroxidase. For protein detection, the peroxidase substrate (DAB) is added, which 
is converted into a brown reaction product. After counter staining with hematoxylin, the 
tissue slides were analyzed by light microscopy (Leica DM4000B) (paper V). 
Liver tissue clarification 
To visualize protein expression in a 3D liver specimen, liver clarification was performed. In 
brief, samples were fixed with 2% paraformaldehyde overnight at 4°C. Samples were then 
sectioned using a vibratome and blocked overnight using Innovex Background Buster. The 
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tissue was incubated with protein-specific primary antibodies mixed in buffer containing 10% 
human serum and 0.1% Triton X-100 in TBS, followed by an incubation with the 
corresponding fluorescently-tagged isotype-specific secondary antibodies together with DAPI 
staining. Next, the tissue clarification was performed using Ce3D clearing media as 
previously described (275). After mounting, samples were analyzed with a Nikon Ti-E 
spinning-disk confocal microscope (20x air/ 60x oil immersion Nikon objective, Andor EM-
CCD camera) (paper V). 
3.8 STATISTICS 
Graph Pad Prism version 6 and 7 were used for statistical analysis. Data were tested for 
normal distribution using D`Agostino-Pearson omnibus normality test. Normally distributed 
data were analyzed using Student´s paired or unpaired t-test, one-way ANOVA, or Pearson 
correlation, whereas non-normally distributed data were analyzed with Wilcoxon matched 
pairs signed rank test, Mann-Whitney test, Kruskal-Wallis test, or Spearman correlation. 
  
  30 
4 RESULTS AND DISCUSSION 
4.1 NK CELLS IN ACUTE DENGUE VIRUS INFECTION 
NK cells have been shown to respond to a variety of viral infections in humans (146, 148, 
149, 151, 152, 154) including flaviviruses (147, 153, 157, 276). However, few longitudinal 
studies characterizing NK cell responses during the very first days of acute viral infections 
and beyond have been performed in humans. Instead, human (live virus vaccination) and 
murine (infection) model systems have been used to study NK cells in this setting (145, 157, 
277). We therefore set out to perform a comprehensive analysis of the very early NK cell 
response during acute DENV infection and followed the patients into convalescence. For this, 
blood samples from 25 DENV-infected patients suffering from DF and 18 community-
matched controls were collected at Tan Tock Seng Hospital in Singapore (paper I). 
4.1.1 Less mature NK cells respond during acute dengue virus infection 
NK cells from patients with DENV infection were highly activated during the acute phase of 
the infection with a markedly increased expression of the proliferation marker Ki67, the early 
activation marker CD69 (Figure 6), as well as CD38. This activation was transient and 
returned to levels that were comparable to healthy controls in the convalescent phase. This 
response was similar to what has been reported for early NK cell responses in infections with 
hantavirus (146), TBEV (147), and in YFV vaccination (157). In line with this, other studies 
reported early NK cell activation in DENV-infected patients (155, 156) and a negative 
correlation between NK cell numbers and DENV infection disease severity. We could not 
observe any changes in NK cell frequency throughout the infection and due to only one 
patient being diagnosed with more severe disease (DHF), it was not possible to correlate NK 
cell frequency or activation with disease severity. CD69 and Ki67 were expressed in an 
almost mutually exclusive pattern. The highest frequency of Ki67+ cells was observed in the 
CD56bright NK cell compartment and among the less mature cells of CD56dim NK cells. This 
seemingly mutually exclusive expression of CD69 and Ki67 was previously shown for NK 
cells (157) and T cells (278) during acute infections with YFV and HIV-1, respectively. 
These distinct subsets of either Ki67- or CD69-expressing cells could represent different 
populations being activated. Alternatively, NK cells might go through different stages of 
activation, with initial expression of CD69 as an early activation marker, subsequently 
followed by Ki67 indicating proliferation (157) and potential downregulation of CD69. 
Indeed, extensive cycling has been shown to downregulate CD69 expression in T cells (279). 
Notably, the magnitude of proliferation detected during acute DENV infection was stronger 
than in infection with TBEV and YFV vaccination (147, 157) and more in line with the NK 
cell response shown in hantavirus infection (146). A similar pattern with respect to CD69 
expression was present when comparing response levels in acute DENV infection with other 
infections (147, 157). Even though CD69 is classically described as early activation marker, 
it has more recently been appreciated for its function in relation to regulating lymphocyte 
tissue-residency (16, 100), and CD69 expression could therefore indicate tissue-homing of 
NK cells. Homing of NK cells to peripheral tissues during acute infection could also be an 
explanation for the stable NK cell frequencies observed despite concurrent robust 
proliferation. Alternatively, ongoing proliferation and stable frequencies of cells could also 
indicate increased levels of apoptosis. However, we observed only a very modest decrease in 
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Bcl-2, and despite the lack of absolute cell counts supporting these results, this speaks against 
significant NK cell apoptosis during acute DENV infection. 
 
Figure 6: NK cells are highly activated during the acute phase of acute DENV infection. 
Both CD69 and Ki67 are upregulated during the acute phase of the infection, a response that 
is transient and returns to levels comparable to healthy controls. 
To investigate the phenotype of responding NK cells in more detail, we took advantage of 
SNE, an algorithm designed for clustering high-dimensional data according to phenotypic 
similarities in order to display multivariate relationships as two dimensional representations. 
This enabled us to visualize phenotypic differences between the responding (Ki67+) and non-
responding (Ki67-) cells in an unbiased way (280). In the SNE analysis, based on 11 
phenotypic markers, we only found minor differences in the CD56bright NK cell compartment. 
However, Ki67+ CD56dim NK cells displayed a less mature phenotype with higher expression 
of NKp30 and NKp46 and lower expression of CD57, NKG2C, and DNAM-1 as compared 
to Ki67- cells during acute DENV infection. This phenotype argues against an expansion of 
memory-like NK cells with high expression of NKG2C and CD57 (mature phenotype) that 
has been shown to expand in some infections (146, 148, 151, 158) but not in others (160, 
161), including TBE (147). Nevertheless, the recent association of NK cells with memory-
like recall responses during infections raises the questions about (a) which NK cell subsets 
are activated during secondary DENV infection and (b) whether a new population of NK 
cells is recruited during each subsequent infection. For our studied cohort, no information on 
primary/secondary/tertiary infection was available, and the respective analysis could 
therefore not be performed. Instead, the activation of primarily immature NK cell subsets in 
our study indicates a cytokine-mediated activation (157, 281) that could potentially occur in 
lymph nodes, where NK cells reside more frequently during inflammation and might be 
primed by activated DCs (139, 277). 
4.1.2 IL-18-induced signaling plays a role in NK cell activation and is uncoupled 
from NK cell education 
In order to get further insights into the mechanisms involved in the NK cell response 
observed, we addressed the role of KIR-mediated education and the possible involvement of 
cytokine-priming. KIR acquisition and education is a process occurring in parallel to 
maturation, and although our results showed the response to be dominated by less mature NK 
cells, the role of education is less clear in infectious conditions in humans. Moreover, 
flaviviruses have been shown to upregulate MHC class I expression in infected cells, which 
might enable evasion from NK cell-mediated recognition via inhibitory KIRs (282, 283) or 
activation in the context of KIR2DS2 and HLA-C (168). An experimental mouse model with 
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MCMV revealed the NK cell response to be dominated by uneducated cells, whereas human 
CMV infection drives the expansion of educated NK cells (160, 163). In other human model 
systems of acute viral infection, however, the degree of NK cell proliferation was 
independent of the education status, indicating that cytokine responsiveness is uncoupled 
from education (157, 281). This is in line with our results, showing that both educated and 
uneducated NK cells contributed to a similar extent to the NK cell response during acute 
DENV infection. 
Next, we wanted to explore the role of NK cell activating cytokines in the preferential 
activation of less mature NK cells during acute DENV infection. To this end, we analyzed 
soluble factors in plasma from the acute phase and found that the NK cell-activating 
cytokines IL-12, IL-15, and IFNa were significantly increased, albeit present only at low 
levels. In contrast, IL-18 levels were high and significantly elevated during the acute phase of 
the infection. NK cell priming with IL-18, together with IL-12, is important to drive IFNg 
production (14, 284). In experimental model systems, the combination of IL-12 and IL-18 
was shown to drive NK cell activation/proliferation (285-288) and to be critical in the early 
stage of viral infections, including MCMV, influenza, and vaccinia virus (285, 287, 289). 
Interestingly, we found the IL-18Ra receptor to be highly expressed on CD56bright NK cells 
and lower on CD56dim NK cells. Within the CD56dim NK cell subset, IL-18Ra expression 
was highest on less mature cells (NKG2A+ CD57-) as compared to terminally differentiated 
(NKG2A-CD57+) NK cells. Furthermore, we studied phosphorylation of IL-18 signaling 
components known to regulate the cell cycle and survival (290-293). Phosphorylation of 
nuclear factor-kB (NF-kB), AKT (known as protein kinase B), activating transcription factor-
2 (ATF2), and the forkhead transcription factor FOXO3A was substantially increased in NK 
cells ex vivo in patients during acute DENV infection. ATF2 promotes proteins involved in 
driving the cell cycle, such as cyclins and anti-apoptotic molecules (290). FOXO3A, located 
downstream of AKT, inhibits proliferation in its unphosphorylated form and translocates, if 
phosphorylated, into the cytoplasm for degradation (291). NF-kB is multifunctional and 
induces pro-inflammatory cytokines, adhesion molecules, anti-apoptotic proteins, chemokine 
receptors, and activation markers, including CD69 (292). This is in line with the induced 
activation and proliferation in NK cells we observed during the acute phase of the infection. 
However, it is unlikely that IL-18 is the sole mediator of NK cell activation and most likely 
acts in concert with other NK cell activating cytokines, such as IL-12, IL-15, and IFNa, 
which are produced upon activation of the initial targets of DENV, including DCs (294) and 
macrophages (139). These cytokines may activate NK cells that in turn increase phagocytosis 
and DC maturation by secreting IFNg (145). IFNg production also contributes to Th1 
polarization of CD4+ T cells that are potent inducers of antigen-specific CD8+ T cell 
responses (295). DCs have also been shown to produce TNF, IL-6, and IL-10 during DENV 
infection (294), which were all, including IFNg, found to be elevated in patient plasma during 
acute infection. This is in line with what has been observed during acute infection with 
hantavirus (Puumala). Hantavirus is another virus that can cause hemorrhagic fever, where 
the above-mentioned cytokines, in addition to IL-18, can be elevated (personal 
communication with K. Maleki). Interestingly, DENV has been reported to interfere with the 
production of IFNa, which may explain the relatively low, but still significantly increased 
IFNa levels detected. Moreover, elevated levels of IFNa together with sTRAIL are 
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associated with mild dengue disease (296). Nevertheless, in the context of DENV infection a 
combination of IFNa and TNF or IL-18 was shown to activate NK cells (297) or gd T cells 
(298), respectively. Moreover, for NK cells this response occurs in a contact-dependent 
manner (297). In this regard, it is noteworthy that IL-15 is rarely secreted and mainly trans-
presented while being bound to IL-15Ra (299). Transpresented IL-15 has been shown to 
drive activation and proliferation of NK cells in hantavirus infection (300). Despite the 
potential role of other NK cell activating cytokines, high levels of IL-18 are produced in skin 
compared to other tissues (GTEx Multi Gene Query database). IL-18 levels were even further 
increased in skin blisters from DENV-infected patients compared to healthy controls (own 
results, data not shown), suggesting that cytokine levels may differ at the site of infection as 
compared to patient plasma. 
4.1.3 NK cells potentially home to the skin during acute dengue infection 
Besides rapid recruitment of immune cells to target organs (142), NK cell functionality is 
important for viral control. We found NK cells to be fully functional in response to cytokine-
priming as well as to target cell stimulation during acute DENV infection. This was 
somewhat surprising since NK cell functionality has been shown to be affected during the 
acute phase in other viral infections. During acute TBEV infection, CD56dim NK cells were 
functionally impaired upon target cell stimulation but responded well to cytokine stimulation 
(147). However, contrary to TBEV infection, NK cell functionality was boosted after YFV 
vaccination, indicating cytokine priming of NK cells in vivo (157). 
Next, we sought to evaluate whether these responding and functional NK cells were primed 
for homing to those peripheral tissues that DENV-infected patients have disease 
manifestations in, such as skin, liver, and gut (138). In this regard, the presence of 
maculopapular skin rashes is associated with milder disease, which suggests an involvement 
of anti-viral immune responses (301). Our results revealed a high and increased expression of 
CLA, CCR5, CXCR3, and CXCR6 in the responding (Ki67+) compared to the non-
responding (Ki67-) CD56bright NK cell compartment. Furthermore, we detected a modest 
expression of CCR2 and CCR6, as well as a significant increase, but still low expression of 
CCR9 and CX3CR1, whereas CCR7 was down-regulated. Responding CD56dim NK cells had 
a similar profile but generally expressed lower levels of homing molecules, especially for 
CLA, CXCR3, and CCR7. As compared to Ki67-expressing NK cells, CD69+ CD56bright NK 
cells presented with a partly deviating adhesion molecule profile with high expression of 
CCR5 and CXCR6, intermediate expression of CCR6, but very low expression of CLA. 
The high expression of CLA indicated that responding (Ki67+) CD56bright NK cells may be 
primed for skin homing during acute DENV infection. E-cadherin, a ligand for CLA, has 
been reported to be upregulated during inflammation in the skin (182). Furthermore, 
CD56bright NK cells have been shown to accumulate in psoriatic skin driven by the migration 
towards CXCL10 and CCL5, binding to CXCR3 and CCR5, respectively (180). In the same 
study, the authors could also demonstrate modest expression of CCR6 and low levels of 
CCR2, CCR4, and CCR7, which is in line with the phenotype we observed. Interestingly, 
keratinocytes respond to (and produce) IL-18 by producing CXCL10 that might attract 
CXCR3+ NK cells or T cells (141, 302) that in turn produce IFNg, which potentiates 
keratinocyte activation (91). As compared to skin-homing NK cells, CCL27-mediated 
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attraction via CCR10 has been reported for CLA+ T cells (185). Of note, Rivino et al. could 
recently demonstrate that DENV-specific T cells migrate to the skin during acute infection, 
with a phenotype mirroring the phenotype of responding CD56bright NK cells we observed in 
our study, expressing homing receptors including high expression of CLA, CCR5, and 
CXCR3 (141). Indeed, we could also detect these NK cells being present in skin blister fluid 
from acute DENV-infected patients with NK cells highly expressing CLA and CD69. 
CXCR6-expressing NK cells have been shown to be highly enriched in the liver (303). In this 
regard, increased CXCR6 expression on NK cells during acute DENV infection could be 
indicative of potential liver homing by these cells. Hudspeth et al. demonstrated the presence 
of CXCR6+CCR5+ CD56bright NK cells binding to CXCL16 and CCL3 in the liver (177). 
Staining of liver biopsies identified LSECs and KCs as targets of DENV (304). Interestingly, 
in a mouse model, infiltrating NK cells were shown to cause liver damage at early stages of 
the infection (305). However, the role for human NK cells possibility infiltrating liver in 
severe DENV infection still remains to be explored. 
4.1.4 Concluding remarks on NK cells in acute DENV infection 
To conclude, we found less mature NK cells to be highly activated and proliferating during 
the acute phase of the infection. We further identified a potential role for IL-18 in driving this 
response. NK cells retained their functional capacity throughout infection and exhibited a 
homing receptor profile indicative for skin homing. Future experiments are needed to address 
the role of NK cells in disease severity with larger patient cohorts with DF and DHF patients. 
Furthermore, it would be interesting to evaluate differences between primary and secondary 
infection in regards to potential NK cell subsets being activated. Finally, in vitro infection 
assays may reveal further insights into the activation of NK cells upon DENV infection. To 
further investigate tissue homing properties, tissues from different organs including skin and 
liver should be collected to investigate the presence of an increased NK cell infiltration as 
well as their homing receptor profile. 
4.2 NK CELL AND HBV-SPECIFIC T CELL RESPONSES AFTER STOPPING 
NA THERAPY IN CHB PATIENTS 
The goal of CHB therapy is to achieve a functional cure, which is defined as undetectable 
HBsAg and HBV DNA in serum with or without HBsAg seroconversion, and to maintain 
lifelong viral control without anti-viral therapy (187). Despite NA treatment, less than 1% of 
CHB patients achieve functional cure each year (201) and it has been estimated that the 
median time until HBsAg clearance is 52.2 years of treatment (196). Therefore, new 
strategies are needed to achieve a higher degree of HBsAg loss (215). As such, NA cessation 
was shown to accelerate HBsAg loss at long-term follow up (197, 199, 202). 
In order to gain further insights into the underlying immunological mechanisms, we 
investigated peripheral blood NK cell and T cell responses at treatment termination as well as 
at week 4, 8, and 12 following NA cessation (paper II and III). To this end, 15 HBeAg 
negative non-cirrhotic CHB patients, who had all been on long-term NA treatment, were 
included in this prospective study (paper II and III). Furthermore, 10 healthy individuals 
(paper II and III) and 4 CHB patients with continuous NA treatment sampled longitudinally 
(paper III) were included as controls. A detailed description of the cohort and the virological 
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outcome was reported by Siederdissen and colleagues (203). Thirteen out of 15 patients 
experienced a virological relapse starting at week 4 after stopping treatment, which was 
followed by a biochemical relapse, peaking at week 8 and week 12, respectively. Most 
patients were re-treated at week 12. HBsAg levels were stable before and throughout short-
term follow up with three patients clearing HBsAg at long-term follow up (Figure 7) (203). 
4.2.1 Phenotypic imprint of CHB and NA cessation on NK cells and T cells 
A previous report exploring early events after stopping NA treatment in the same cohort 
revealed a potent induction of cytokines and chemokines (203). Hence, re-occurrence of viral 
replication may affect immune responses. At baseline, however, no changes in peripheral 
blood NK cells (paper II) or T cells (paper III) could be detected after long-term NA 
treatment as compared to healthy controls. This is in contrast to what has been reported for 
untreated CHB patients, showing increased levels of CD56bright NK cells (216-218) and was 
more in line with the unaltered distribution of NK cells when treated with NAs (216, 230). 
Moreover, this is also in contrast to the increased frequency of CD56bright NK cells (231-233) 
during pegIFNa therapy, which is accompanied by a loss of CD8+ T cells (231). 
Next, we investigated the potential effect of stopping NA therapy on the NK cell and T cell 
phenotype. Using unsupervised SNE analysis, our data revealed major differences between 
healthy controls and CHB patients before stopping NA treatment (Figure 7), which indicates 
a general imprint of HBV infection on immune cells (paper II and III) (208). NK cells 
(paper II) exhibited an increased expression of CD57 and pan-KIR and lower expression of 
NKG2A. Lower NKG2A and higher CD57, and KIR expression indicates the presence of a 
more differentiated NK cell compartment (47). As opposed to our results, a meta-analysis of 
NK cells in CHB demonstrated increased expression of activating receptors. Moreover, we 
observed lower expression of CD16 and NKp30, which is in line with previous reports (221) 
on NA-treated patients. Furthermore, we detected lower expression of Siglec-7. The lack of 
Siglec-7 was associated with a dysfunctional NK subset in HCV (306), which might suggest 
some degree of dysfunctionality in the NK cell compartment also in CHB. Additionally, a 
report by Boni et al. showed that NK cells in naïve CHB patients have an 
activated/inflammatory phenotype (TRAIL+, Ki67+, CD38+) that normalized upon NA 
treatment (217). Thus, our results are more in line with this latter quiescent phenotype. IFNa 
has been reported to be induced during natural flares of HBV (219) and was shown to initiate, 
together with concomitant IL-8, NK cell-mediated killing of hepatocytes and/or HBV-
specific T cells via TRAIL (219, 226). Tan et al. (307) demonstrated, more in line with our 
results, that IL-8 and CXCL9-10 were the only inflammatory mediators being upregulated 
without inducing TRAIL expression in flares upon stopping NA treatment. We also reported 
on the absence of the early activation marker CD69 and TRAIL. Both markers are induced by 
IFNa (231, 232), hence, the lack of IFNa detected in our cohort (data not shown) would 
explain this phenotype. Lack of IFNa is more in line with the cytokine pattern observed 
during acute HBV infection (150). This suggests that we might have missed NK cell 
activation occurring at a time point earlier than 4 weeks after stopping therapy. Alternatively, 
IL-10 that was shown to be upregulated at week 4 after treatment discontinuation (203), 
might have dampened NK cell activation (218).
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When analyzing T cells via SNE analysis, our data revealed an imprint of CHB infection 
(paper III) with down-regulation of CCR7 and CD45RA and, hence, an increased frequency 
of TCM and TEM cells within both CD4+ and CD8+ T cells as well as more TEMRA cells among 
CD8+ T cells. Additionally, we confirmed a more differentiated phenotype for CD8+ T cells, 
indicated by higher expression of CD57 and KLRG1. Furthermore, PD-1 expression was 
increased for both CD4+ and CD8+ T cells, which has been described as an inhibitory 
molecule typically expressed on exhausted T cells in CHB (235). 
Following NA termination, only minor phenotypical changes could be observed for NK cells 
(paper II), whereas T cell markers associated with exhaustion were slightly altered (paper 
III), including an upregulation of PD-1 and down-regulation of TCF-1. TCF-1+ T cells have 
been associated with sustained viral control during chronic infections and were described to 
give rise to TCF- T cells exhibiting an increased effector potential (247). Our results showed 
that TCF-1 down-regulation occurred at week 4 when HBV DNA levels increased. Next, we 
compared the patients who cleared HBsAg at long-term follow up to the remaining cohort. In 
this analysis, we observed an increased expression of the activation marker CD38 on NK 
cells at week 12 (paper II). Furthermore, the frequencies of both KLRG1+PD1+ CD4+ and 
CD8+ T cells of patients who cleared HBsAg were below the mean frequency of the cohort at 
baseline and thereafter. Moreover, the patients who achieved functional cure also had higher 
levels of CD38+ Ki67+ T cells that correlated with the HBsAg fold decline (week 48 
compared to baseline) (paper III). Together, these results show only minor phenotypic 
alterations of NK cells and T cells (paper II and III) and indicate that T cells from patients 
with subsequent HBsAg loss display a less exhausted and more activated phenotype (paper 
III). 
4.2.2 Increased natural cytotoxicity responses are temporally correlated with liver 
damage and HBsAg loss 
Several studies have demonstrated a functional impairment of the NK cell compartment in 
CHB (217, 218, 221, 222, 227) with retained cytotoxicity, but a decreased capacity for 
cytokine secretion (218, 221, 222). During anti-viral therapy, this functional dichotomy was 
reported to be unaffected (217) or improved (221). In order to investigate NK cell 
functionality after long-term NA treatment at baseline and after stopping NA therapy, we 
stimulated NK cells with different target cells (K562 cells, 721.221 cells, and rituximab-
coated 721.221 cells) to test their capacity for performing natural cytotoxicity and ADCC, 
and evaluated NK cell functionality upon cytokine stimulation (IL-12+IL-18) (paper II). A 
simultaneous evaluation of five functional readouts (CD107a, IFNg, TNF, MIP-1b, and GM-
CSF) revealed only minor differences when comparing NK cell responses at baseline with 
healthy controls, with reduced functionality upon cytokine priming, particularly in the 
CD56dim NK cell compartment. Stopping NA therapy however, significantly boosted NK cell 
natural cytotoxicity responses, degranulation, and IFNg, TNF, and GM-CSF production, 
which reached significance for CD56dim NK cells (Figure 7). Hence, NA treatment cessation 
boosted NK cell multifunctionality at week 12. Interestingly, stopping NA treatment also 
induced cytokine and chemokine production in this cohort at the time of virological relapse 
(203), including IL-12 that is known as an NK cell-stimulating cytokine. On the other hand, 
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simultaneous induction of IL-10 (203) may impact NK cell functionality as previously shown 
by Peppa and colleagues (218). 
Interestingly, we detected positive correlations between natural cytotoxicity-induced 
functional responses upon stimulation with K562 cells for CD56dim NK cells and ALT-levels 
at week 8 and week 12 (Figure 7), the time points of the peak of HBV DNA and ALT, 
respectively. Interestingly, high ALT after treatment cessation was associated with HBsAg 
loss at long-term follow up (203), which was in line with other studies (201, 202), including 
a study evaluating HBsAg loss in more than 5.400 CHB patients receiving NA treatment 
(201). Very few correlations were found for other time points or between NK cell phenotypic 
and clinical parameters. Together, this may indicate a contribution of NK cells to the liver 
damage following viral relapse as shown for patients with CHB (222) and in contrast to 
natural flares or IFNa therapy. Natural flares and IFNa therapy are both associated with an 
upregulation of TRAIL (219, 233, 308) and reduced functionality (233, 308), but also with 
potential TRAIL-mediated killing of hepatocytes (219). However, our findings were based on 
prototypic target cell lines and need to be confirmed in a more physiological setting. 
When comparing donors who cleared HBsAg to the remaining donors in the cohort, NK cells 
from the functionally cured group displayed increased NK cell responses towards K562 cell 
stimulation in particular in the CD56dim NK cell subset. The latter also expressed high levels 
of CD38 as shown for the patients experiencing HBsAg loss. 
 
4.2.3 Increased HBV-specific T cell responses upon NA cessation 
HBV-specific T cells are believed to be important for viral clearance (235), but are 
functionally impaired (235-237) and rarely detectable in CHB patients (235). Therefore, 
therapy aims at boosting the magnitude and quality of virus-specific immune responses (215). 
Since T cell function is affected by the viral load (235, 237), and NA therapy partially 
restores HBV-specific T cell responses in vitro (250, 251), we set out to explore HBV-
specific T cell functionality in patients after stopping NA therapy (paper III). HBV-specific 
T cell responses were evaluated upon stimulation with core-, polymerase-, or envelop-
specific overlapping peptides. Our data revealed that HBV-specific CD4+ T cells significantly 
Figure 7: Graphical summary of 
NK cell responses during NA 
cessation in CHB. Clinical 
characteristics of CHB patients 
undergoing structured NA 
interruption (top). Phenotypical 
changes of NK cell at baseline 
(middle) and increased natural 
cytotoxicity responses at week 12 
after treatment cessation (bottom). 
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increased IFNg production starting at week 4 after treatment cessation and peaked at week 12. 
Furthermore, an increased production of MIP-1b was detected at weeks 8 and 12. HBV-
specific CD8+ T cells showed an increase in IFNg production at week 12 following treatment 
discontinuation. Increased IFNg production was also reported in an early study by Tan et al., 
who however, only observed functional improvement in one out of five patients after NA 
withdrawal (307). In addition, our results revealed improved multifunctionality at 8 and 12 
weeks following treatment cessation with an increased T cell population exhibiting 2 or 3 
functions including degranulation and cytokine production simultaneously for both HBV-
specific CD4+ and CD8+ T cells. This functional boost was only detected upon stimulation 
with core-specific, but not for polymerase- or envelop-specific peptides. 
Importantly, some degree of heterogeneity in HBV-specific T cell responses was observed on 
an individual patient basis. Considering responsiveness to different epitopes being present in 
four different core-specific peptide pools, some patients had a low or strong fluctuation in 
their T cell response. Nevertheless, stopping NA treatment increased IFNg production of 
HBV-functional T cells at least 3-fold for 50%-70% of the patients at week 4 to week 12. 
Notably, patients who subsequently lost HBsAg did not have the strongest HBV-specific T 
cell responses, and no correlations were found between the T cell response and the clinical 
data or HBsAg loss. As opposed to our results, Boni et al. could show that the magnitude of 
the HBV-specific T cell response correlated with HBV DNA in flares of HBeAg positive 
patients (235). In line with this concept, T cell responses seemed to be associated with the 
viral rebound in most patients, but also decreased while HBV DNA was continuously 
increasing. This indicates that increasing HBV DNA levels promote T cell responses by 
peptides being presented by newly infected hepatocytes together with a modified cytokine 
milieu (203, 309). Alternatively, increasing HBV DNA levels might induce T cell exhaustion 
by chronic exposure to antigen (235). In this study, however, early re-treatment might have 
masked this association. In order to rule out spontaneous fluctuations, and considering the 
presence of only one baseline sample per patient, four CHB patients with continuous NA 
treatment were recruited. These patients showed barely detectable HBV-specific T cell 
responses and only minimal fluctuations over time. 
Exhausted HBV-specific T cells have been shown to express the inhibitory receptor PD-1 
(235). PD-1/PD-L1 blockade is considered a potential strategy to boost T cell functionality in 
diverse clinical settings including HBV treatment (235, 241, 242). Indeed, we could show 
that a stimulation with core-specific peptides together with blocking PD-L1 significantly 
boosted CD4+ and CD8+ T cell responses, reaching a 2-fold increased IFNg production in 
around 50% of the patients at week 8 following treatment discontinuation. In contrast to 
polymerase-specific T cell responses, PD-L1 blockade also induced a significant increase in 
envelop-specific T cell responses at week 12 as well as significantly increased 
multifunctionality upon stimulation with core-specific peptides at all time points studied. PD-
1 expression may however be a mechanism to prevent excessive liver inflammation, and PD-
L1 blockade could potentially cause T cell-mediated adverse events. Interestingly, Rivino and 
colleagues demonstrated that patients without flare after NA withdrawal had more vigorous T 
cell responses during therapy and that these cells were mainly found within the PD-1+ T cell 
fraction (253). This suggests a role of PD-1 in preventing over-stimulation of HBV-specific T 
cells. However, in the study by Rivino et al, results were not evaluated in regard to immune 
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function after stopping therapy or treatment outcome. Furthermore, mitochondrial 
dysfunction has been linked to be driving T cell exhaustion with an improvement of T cell 
functionality by using mitochondria-targeted antioxidants, such as MitoTempo (310). 
Intriguingly, we could show that the addition of MitoTempo improved T cell functionality in 
vitro in two patients at a level comparable to PD-L1 blockade. 
4.2.4 Conclusion and future perspectives on immunological events after NA 
discontinuation 
The magnitude and function of the immune response seem to direct the outcome of HBV 
infections towards either an acute resolving infection or CHB. Thus, in order to establish 
long-term control of the virus, the aim of immunotherapy is to restore HBV immunity (215). 
Here, we reported augmented NK cell natural cytotoxicity responses in HBeAg negative 
CHB patients at week 12 following treatment cessation that were associated with liver 
damage that was more pronounced in patients achieving HBsAg loss (paper II). 
Furthermore, we demonstrated that HBV core-specific T cell responses were boosted upon in 
vitro peptide stimulation after treatment discontinuation, a response that was further 
augmented using PD-L1 blockade (paper III). However, we could not find an association 
between HBsAg loss and HBV-specific T cell functionality and detailed correlations are not 
possible to perform since only three patients subsequently lost HBsAg. Therefore, our 
findings need further confirmation using larger cohorts. Nevertheless, we can speculate that 
the quantity of the response is less important than the quality. Also, our study design 
restricted NK cell and T cell analysis to only week 4, 8, and 12 after stopping treatment 
(paper II and III). HBsAg loss, however, occurred at long-term follow up and it would 
therefore be important to study immune responses at later time points. Additionally, early 
retreatment may have limited further induction of immune responses and/or avoided T cell 
exhaustion. To gain additional insights into immune responses occurring after stopping NA 
therapy, a direct analysis of immune cells in the intrahepatic environment is needed to 
understand the mechanisms underlying HBV control. In that regard, Pallet et al. showed that 
CD8+ TRM cells were enriched in HBV-infected livers compared to healthy livers and 
expressed significantly more PD-1. Interestingly, the frequency of intrahepatic CD8+ TRM 
cells was inversely associated to viral load with the highest frequency in patients with well-
controlled infection. These cells were maintained and functional in patients who had achieved 
functional cure (115). Additionally, the intrahepatic CD8+ TRM cells constituted a major 
fraction of HBV-specific T cells in HBV infected livers with the capacity to produce IFNg, 
TNF, and IL-2 (115) with IL-2 being absent or low upon peptide stimulation of peripheral 
blood derived T cells (252). Moreover, restoration of T cell functionality upon PD-1 pathway 
blockade has been shown to be more efficient in the intrahepatic compartment as compared to 
peripheral blood (236). 
From an NK cell perspective, HBV infection is known to affect NK cell receptor ligands on 
hepatocytes (207, 226) and HBV-specific T cells (226). Despite potential viral escape from 
NK cell recognition, NK cell activation has been shown to inversely correlate to HBsAg 
levels in CHB patients (311). Alternative treatment approaches are currently being tested 
including targeting mitochondrial dysfunction, therapeutic vaccination, or combination 
therapies (215). Furthermore, experimental approaches using methods allowing for a broad 
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analysis of immune-related markers, such as RNA sequencing, will aid the biomarker 
discovery. In conclusion, stopping NA therapy is a favorable treatment option for a selective 
group of patients and may be combined with other treatment strategies to boost HBV-specific 
immunity. 
4.3 ASSESSMENT OF MAIT CELLS IN PSC 
MAIT cells are highly enriched in the liver (312) and are well known for their anti-microbial 
functions and role in inflammatory conditions (72). Interestingly, MAIT cells have been 
shown to localize around bile ducts in portal tracts (272). Together, this suggests MAIT cells 
to possess an important function in liver immune surveillance (313). For this reason, we 
studied MAIT cells in PSC, a chronic inflammatory disease of the bile ducts that is often 
associated with concomitant IBD (paper IV). We used a cohort of 28 PSC patients of whom 
23 had PSC and IBD, and five patients with PSC only. Twelve healthy subjects were 
recruited as controls. Additionally, seven IBD patients and eight patients with primary biliary 
cholangitis (PBC), another autoimmune cholestatic disease of the small intrahepatic bile 
ducts, were included as diseased controls. To investigate the presence of MAIT cells in the 
biliary epithelium, we used cells acquired from biliary brush samples collected during ERCP 
of PSC patients and as controls, patients undergoing ERCP for other reasons with no 
suspicion of biliary inflammation (paper IV and paper V). 
4.3.1 MAIT cell frequencies are decreased in blood but retained in bile ducts 
In order to gain further insights into the role of MAIT cells in PSC, we first investigated their 
presence in peripheral blood in PSC patients and controls. MAIT cells were severely reduced 
in PSC patients and disease controls as compared to healthy controls. This is in line with 
other studies that reported a selective loss of MAIT cells in chronic inflammatory liver 
diseases, such as chronic HCV (314), non-alcoholic steatohepatitis (NASH) (315), alcoholic 
liver disease (316), PSC, and PBC (315). This suggests that the loss of MAIT cells is not 
specific for biliary inflammatory diseases. Indeed, a severe reduction of MAIT cells has also 
been shown for patients with, among other chronic inflammatory diseases, systemic lupus 
erythematosus (317), type 2 diabetes (318), and IBD (84, 319). Interestingly, MAIT cells 
have been shown to home to the inflamed intestine in IBD (84, 319) and were also shown to 
infiltrate the portal tracts of the liver in chronic inflammatory liver disease (272). To test 
whether MAIT cells are present in the biliary epithelium, we analyzed cells acquired from 
biliary brush samples. As compared to peripheral blood, MAIT cells were found to be four 
times increased in bile ducts. The frequency and absolute number of biliary MAIT cells in 
PSC did not differ as compared to non-PSC controls, suggesting that MAIT cells are retained 
at the site of inflammation in PSC. 
4.3.2 Peripheral blood MAIT cells are phenotypically activated, but dysfunctional in 
PSC 
To investigate the potential activation of MAIT cells in PSC, we evaluated the phenotype 
using SNE analysis and found an increased expression of CD69, CD56, and NKG2D and 
decreased expression of CD28, CD127, and CXCR6. Some of these findings could be 
recapitulated with manual gating. Conventional gating revealed an increase in CD39, an 
ectonucleotidase being associated with terminally exhausted T cells (320), and PD-1, a 
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marker of exhausted/recently activated cells (320). CD69 is classically seen as an activation 
marker in peripheral blood, whereas CD56 was associated with a subset of MAIT cells with 
high expression of IL-12R, IL-18R, Eomes, and T-bet (75). CD28 and CD127 may get down-
regulated upon MAIT cell activation or after cytokine stimulation (66, 321). A decrease of 
CXCR6, which is associated with migration to the liver, could indicate that MAIT cells have 
homed to the liver. Interestingly, this activated phenotype was not unique for PSC and also 
seen in IBD and PBC patients, suggesting that this is a common MAIT cell phenotype in 
chronic inflammatory diseases. Indeed, an activated (“exhausted”) phenotype was reported in 
other chronic inflammatory diseases, including autoimmune hepatitis, NASH (315), alcoholic 
liver disease (316), type 2 diabetes (318), HIV-1 (322), and HCV (314). 
Finally, we set out to test the function of the remaining MAIT cell population in blood upon 
stimulation with E. coli or cytokines (IL-12+IL-18). Circulating MAIT cells were 
functionally impaired upon E. coli stimulation with a reduction of CD107a, TNF, IFNg, and 
CD69, which was MR1-dependent, whereas almost no differences were detected upon 
cytokine stimulation, except TNF that was found to be reduced. These results reflect what has 
been shown in chronic HCV (314) as well as the functional impairment of MAIT cells in 
HIV (322). Böttcher and colleagues recently reported functional exhaustion of MAIT cells in 
autoimmune liver diseases, including PSC (315). As opposed to our results, they showed that 
MAIT cells retained their capacity to produce TNF and IL-17. In this regard, HSC-MAIT cell 
co-cultures resulted in activation of HSC with increased expression of pro-fibrotic genes, 
suggesting a contribution of IL-17 produced by MAIT cells to liver fibrosis (315). 
Low frequencies of circulating MAIT cells in chronic inflammatory diseases including PSC 
(84, 314-319) together with the activated phenotype suggest reduced survival due to a 
possible common mechanism. Chronic stimulation in vivo has been proposed to cause MAIT 
cell loss due to activation-induced cell death. This would be in line with an activated 
phenotype that we and others have found, followed by dysfunctionality and finally apoptosis. 
Loss of gut integrity causing increased translocation of intestinal bacteria, bacterial antigens, 
or metabolites was suggested to be the driving force (316, 323). Other diseases, such as HCV 
(314) and alcoholic liver disease (316) are associated with a so called “leaky” gut, which 
could also occur in PSC, considering the high frequency of patients with concomitant IBD. 
To test this hypothesis, markers for microbial translocation can be assessed, including sCD14 
or sCD163 that indicate activation of macrophages, or markers for damage of the intestinal 
epithelium, such as fatty acid binding protein (324). No associations between the loss of 
MAIT cells and clinical characteristics could be found in our cohort. One explanation for the 
missing association might be that all patients had mild disease and larger cohorts with a 
substantial number of patients with more terminal disease would be required. Also, age and 
gender impact MAIT cell numbers of individuals (325) with a possible effect on MAIT cell 
loss, especially in the slight gender/age unmatched PBC group in our study. Hedge et al. 
suggested that MAIT cells themselves drive pro-inflammatory properties of hepatic 
myofibroblasts and monocyte-derived macrophages that in turn secrete IL-6 and IL-8, 
thereby exhibiting a pro-fibrotic function (326). Activated monocytes or macrophages in turn 
may drive MAIT cell activation through secretion of IL-12 and IL-18. Interestingly, Böttcher 
et al. could show that long-term stimulation with IL-12 and IL-18 drives MAIT cell 
exhaustion (315). We, however, did not determine the levels of cytokines in our cohort. 
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Nevertheless, both IL-12 and IL-18 are known to be increased in autoimmune liver diseases 
(315). To further investigate whether MAIT cells are truly exhausted, transcription factors 
can be assessed. Indeed, downregulation of Eomes, T-bet, and RORgt has been associated 
with the loss of effector functions of MAIT cells (83, 316). 
In conclusion, we found a severe reduction of circulating MAIT cells in PSC. Remaining 
MAIT cells exhibited an activated phenotype and impaired MR1-dependent functionality. It 
is yet unclear whether circulating MAIT cells die or home to peripheral tissues in chronic 
inflammatory diseases in humans. Also, it remains to be determined whether MAIT cells are 
protective or harmful, eventually contributing to the development of fibrotic strictures at the 
site of inflammation. 
4.4 EXPLORATION OF THE IMMUNE SYSTEM IN THE BILIARY TREE 
The biliary epithelium is affected by various liver diseases, including PSC (254). BECs serve 
as a mucosal barrier and can sense and respond to pathogens. Furthermore, the bile duct is in 
continuity with the gut flora (121, 268). However, very little is known about the immune 
system within the bile duct. In order to characterize the biliary immune landscape during 
inflammation and at steady state, we developed a new method to assess cells isolated from 
biliary brush samples collected during ERCP and compared those to matched peripheral 
blood (paper V). Samples were taken from inflamed bile ducts of 62 PSC patients and 41 
non-PSC controls. The latter underwent ERCP due to other indications, including bile duct 
stone disease, chronic pancreatitis, malignant stricture, papillary adenoma, post-operative 
stricture, or an unknown stricture. 
4.4.1 Biliary inflammation is associated with cellular infiltration of neutrophils 
Tissue inflammation is generally characterized by infiltration of leukocytes, including 
neutrophils (327). In line with this, we found a five-fold increase of leukocytes and a 
considerably increased number of neutrophils, making up to 30% of the total cellular 
infiltrate, in inflamed (PSC patients) as compared to non-inflamed bile ducts. Since very few 
neutrophils were detected in the non-inflamed control samples, this validates the integrity of 
this group as a control cohort. An increased presence of neutrophils in the inflamed samples 
is not surprising since neutrophils are known to be rapidly recruited during liver 
inflammation, attracted by chemokines or ATP, which is released by necrotic cells (327). 
BECs themselves have been shown to be immunologically active cells and to play a role in 
infectious but also non-infectious hepatobiliary diseases (131, 268). As such, they have the 
capacity to induce inflammation by secreting pro-inflammatory cytokines, including IL-1b, 
IL-6, and TNF, but also CXCL8 (268) that is known for attracting neutrophils. Indeed, 
CXCL8 has been shown to be upregulated in patients with cholestatic diseases, which could 
indicate a general involvement of this pathway in biliary pathologies (126). 
4.4.2 Conventional CD8+ effector memory T cells are the dominant tissue-resident 
population in bile ducts 
Next, we set out to explore the biliary immune system with regard to the presence of IELs. 
IELs have been described to reside and patrol epithelial surfaces in the intestine, lung, and 
skin, where they play an important role in tissue homeostasis and disease (109, 110, 114, 
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328). Therefore, we evaluated the expression of the tissue-residency markers CD69, CD49a, 
and CD103 (100). All markers were expressed by cells from the biliary epithelium with a 
substantial fraction of CD69+CD103+ cells that were highly prevalent among cells isolated 
from bile ducts. Interestingly, these cells were less frequent in the liver parenchyma and/or in 
sinusoidal blood and very low in peripheral blood (Figure 8). This was in line with our 
observation that intra- and extrahepatic BECs expressed high levels of E-cadherin, the ligand 
of CD103 integrin, whereas only low expression could be detected on hepatocytes. Indeed, 
CD69+CD103+ IELs were shown to reside in barrier tissues, and were recently also reported 
to be present in the liver (115, 329). We detected the highest frequency of these cells in 
samples taken from the biliary epithelium, which suggests that intrahepatic CD69+CD103+ 
IELs may be located in proximity to the bile ducts. This further suggests that different 
intrahepatic tissue-resident lymphocyte populations might inhabit distinct niches within the 
liver and that this is regulated by the different tissue-residency markers. 
 
Figure 8: Cells isolated from the biliary epithelium express tissue-residency markers. 
Tissue-resident cells are detected in proximity to bile ducts. Shown is the frequency of 
CD103+CD69+ cells out of live CD45+ leukocytes. 
In order to unravel the composition of the CD69+CD103+ cells compared to circulating 
(CD69-CD103-) cells from bile ducts, a SNE algorithm was used that reduces high 
dimensionality of complex data but keeps multivariate relationships without introducing a 
bias from conventional gating (280). The SNE analysis revealed expression of the tissue-
residency markers investigated with a dominant co-expression pattern of CD69 and CD103. 
Furthermore, the data revealed CD8+ T cells to be the main subset being present within this 
population of tissue-resident cells (Figure 9). This was also accompanied with a CD4+/CD8+ 
T cells ratio shift as compared to peripheral blood towards more CD8 T cells. This is in line 
with what has been reported for IELs in other tissues, including intestine, skin, and lung 
(103). Besides changes in the T cell compartment, we also found minor changes among other 
subsets, including a lower frequency of NK cells and monocytes/macrophages in bile ducts as 
compared to peripheral blood. These findings could be recapitulated with conventional gating 
and were applicable for both inflamed and non-inflamed bile ducts. 
Next, we investigated the nature of the biliary T cell compartment in more detail. Different T 
cell memory subsets can be identified using CCR7 and CD45RA (67). Our results revealed 
that the majority of biliary-resident T cells within both the CD4+ and the CD8+ T cell 
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compartment had a TEM phenotype. The non-tissue-resident T cell population from bile duct 
samples showed a profile similar to peripheral blood with a fraction of naïve T cells, some 
TEM, and a population of TCM within the CD4+ T cell compartment. Generally, CD8+ T cells 
contained a larger population of TEMRA as compared to CD4+ T cells. IELs from the small 
intestine are well-known to contain a major population of TCRab CD8ab effector memory T 
cells (109, 110). Future experiments using microscopy shall address the location of these 
cells in liver tissue. IELs in mice often comprise a population of TCRab CD8aa-expressing 
T cells (108, 109). As opposed to mice, our results revealed that CD8aa co-receptor usage 
was extremely rare among the CD8 T cells in bile ducts, which supports the literature with 
respect to the controversial existence of a CD8aa population in humans (109). Based on 
differences in the tissue microenvironment, however, TCRab CD8aa T cells may still exist 
among IELs at a different location or very low frequency in humans. 
 
Figure 9: CD8+ T cells are the main population within tissue-resident cells in bile ducts. 
SNE analysis showing the abundance of cells from bile ducts (red) and blood (blue). Relative 
expression intensities of single markers with phenotypes being more common in bile ducts 
and blood encircled in red and blue, respectively. 
Unconventional T cells are known to contribute to the pool of IELs (101). In our analysis, 
MAIT cells were enriched and gd T cells slightly increased among tissue-resident cells in bile 
ducts as compared to the circulating population and peripheral blood. MAIT cells are known 
for being enriched in the gut (71, 84), but were also found in other tissues (72, 73, 85, 330), 
including a population expressing CD103 (86, 330). IELs contain a substantial population of 
gd T cells in humans (101). In bile ducts however, they may not be selectively enriched. 
Nevertheless, we generally found higher frequencies of gd T cells in PSC patients than in 
controls. This is in line with earlier reports showing an increase in gd T cells in PSC patients 
in blood and portal tracts (331). Interestingly, gd T cells were also reported to be associated 
with disease severity in patients with IBD (332). Considering the relatively low frequency of 
unconventional tissue-resident T cells, our results revealed that the main population in bile 
ducts was comprised of conventional TCRab CD8ab memory effector T cells. 
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4.4.3 Tissue-resident T cells exhibit a distinct chemokine receptor and functional 
profile 
Cellular migration is guided by environmental cues that direct immune cells to target tissues 
(89, 333). Due to the direct connection with the intestine, we hypothesized that the homing 
receptor expression of tissue-resident and circulating CD8+ T cells from inflamed and non-
inflamed bile ducts might have shared features between liver (CXCR6) and gut (CCR9, 
a4b7). We also evaluated CCR6 and CXCR3 expression, known to be important for homing 
to mucosal or inflamed tissues, respectively (271, 333-335). Bile duct-resident T cells 
displayed a distinct homing receptor profile with high expression of CXCR6 and a4b7 
(Figure 10). Expression of CCR6 and CCR9 was modest but still increased in biliary-resident 
cells as compared to circulating T cells from bile ducts or blood and mostly expressed on 
cells co-expressing CXCR6 or a4b7. The overall homing receptor profile of circulating T 
cells from bile ducts was more similar to the one in peripheral blood as compared to the 
profile of the tissue-resident population (Figure 10). CD8+ T cells from non-inflamed bile 
ducts exhibited a similar profile to the inflamed bile duct with a trend towards higher 
expression of CXCR3 and lower expression of CCR9 as compared to samples from PSC 
patients. Interestingly, not only LSECs but also BECs are known to express membrane-bound 
CXCL16 and also secrete CCL20, which indicates that both CXCR6 and CCR6 may play a 
role in the localization of lymphocytes in the liver (115, 131, 270, 333). Eksteen et al. could 
show that only gut-derived DCs, but not liver DCs, had the capacity to selectively prime T 
cells for gut-homing via CCR9 binding to CCL25 (335). In regard to PSC pathogenesis, it 
was hypothesized that gut-primed T cells home to the liver due to an inflammation-driven 
aberrant expression of CCL25 and MadCAM-1 in addition to liver homing molecules (271, 
336). Indeed, we observed a tendency towards higher CCR9 expression in inflamed bile 
ducts from PSC patients than in non-inflamed bile ducts from controls, substantiating such a 
hypothesis. During inflammation, the CXCR3 ligands CXCL9-CXCL11 are produced by 
hepatocytes, cholangiocytes, and HSC (337) and were shown to promote recruitment of 
CXCR3-expressing cells to the liver in mice (270). High CXCR3 expression was also 
confirmed to a tissue-resident T cell population in human liver (115). Likewise, the 
importance of CXCR3 expression for tissue-localization was also emphasized in other 
organs, such as skin and lung (114, 328). In conclusion, biliary-resident T cells co-express a 
gut and liver homing receptor profile. 
  
Figure 10: CD8+ biliary-resident T cells 
express a gut and liver homing receptor 
profile. Heat map summarizing the 
frequency of expression. Stars and hashes indicate 
statistical difference for the tissue-resident vs. circulating 
population and tissue-resident vs. blood, respectively. 
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IELs are essential for epithelial barrier integrity and protection. Upon excessive activation, 
however, they may contribute to disease (110). We compared the production of cytokines 
upon stimulation with PMA/ionomycin of CD8+ tissue-resident (CD103+) T cells to the 
circulating population (CD103-) from bile ducts as well as to CD8+ TEM cells from peripheral 
blood. Biliary-resident cells produced all investigated cytokines, with the highest production 
of TNF and IFNg. TNF and IFNg were produced by circulating and tissue-resident CD8+ T 
cells to a similar level as well as by peripheral blood CD8+ TEM cells (Figure 11). During 
infection, TNF and IFNg induce upregulation of TLRs, HLA class I and II, as well as 
adhesion molecule expression on BECs (268). This results in increased cytokine production 
and T cell-cholangiocyte cross-talk. Both cytokines also induce chemokine secretion, 
including CCL2, CXCR8 (IL-1b, TNF), and CXCL9-CXCL11 (IFNg), thereby attracting 
other immune cells. The production of TNF and IFNg may also play a role in disease 
pathology by causing epithelial barrier disruption via the induction of apoptosis or reduction 
of tight junction proteins (110, 335). 
We found an increased production of IL-2, IL-17, and IL-22 in the biliary-resident T cell 
population compared to the circulating one from bile ducts or blood (Figure 11). Increased 
production of IL-2 is in line with an earlier report by Pallet et al. (115) and may indicate the 
requirement of IL-2 in an environment with little presence of CD4+ T cells. Also, IL-2RA is 
one of the PSC-associated SNPs although the exact mechanism of action for this SNP to 
potentially contribute to disease is unknown (126). Th17 cell responses have been linked to 
responses to microbes in PSC (266). Both IL-17 and IL-22 are involved in the recruitment of 
neutrophils and the production of anti-microbial peptides (111, 338-340). Generally, IL-17 is 
considered to induce an inflammatory response by secreting cytokines and chemokines, 
including the production of IL-6, GM-CSF, CCL2, CCL20, and CXCL8, leading to the 
chemo-attraction of macrophages, neutrophils, and CCR6-expressing T cells. IL-22 is known 
for its regenerative capacity. However, if IL-17 and IL-22 are not tightly controlled, both 
cytokines can contribute to autoimmune or chronic inflammatory processes (338). In 
summary, biliary-resident T cells are functional with a Th1/Th17/Th22-like profile. 
 
Figure 11: Functional profile of CD8+ T cells from blood and bile ducts. Cytokine 
production from effector memory CD8+ T cells from peripheral blood (line indicates the 
mean) was compared to T cells from bile ducts. The dotted line indicates the background of 
the respective cytokines detected in the unstimulated controls. 
Bile duct injury and chronic inflammation in PSC is known to contribute to concentric 
fibrosis (131, 256). Dysregulated myofibroblasts drive fibrosis with both HCS and portal 
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fibroblasts being engaged in biliary fibrosis initiation (268). Upon injury, cholangiocytes 
themselves promote worsening of liver damage by responding with proliferation, immune 
cell recruitment, and fibrosis initiation, a process termed ductular reaction. IL-6 is produced 
by activated BECs and drives proliferation in an autocrine fashion (131, 268). Additionally, 
cholangiocytes actively contribute to the recruitment of KCs/macrophages that in turn secrete 
pro-inflammatory cytokines and are producers of TGF-b, which is a potent activator of HSC 
(327). Another cytokine implicated in the development of liver fibrosis is IL-17 (327, 341), 
potentially derived from highly functional biliary-resident T cells. IL-17 activates KCs to 
increase cytokine production, including IL-6, IL-1b, TNF, and TGF-b. Moreover, IL-17 
promotes fibrogenic myofibroblast transformation as well as the production of collagen (341) 
and can directly affect cholangiocytes (342). Cholangiocytes in turn augment the production 
of IL-17 by initiating Th17 cell development and recruitment by cytokine and chemokine 
secretion (342). Thus, complex immunologic pathways contribute to fibrosis development 
with both cholangiocytes and recruited immune cells including biliary-resident T cells, 
actively contributing to dysregulation of myofibroblasts. 
4.4.4 Conclusions and future perspectives on biliary-resident T cells 
Using immune cells isolated from brush samples, we established a new method allowing for a 
high resolution single cell analysis of the biliary immune system. We found increased cellular 
infiltration of neutrophils as well as a substantial population of biliary-resident TCRab 
CD8ab effector memory T cells with a distinct homing receptor and functional profile. In 
this study, certain limitations should be considered. Due to low cell numbers, we could not 
evaluate functionality of biliary T cells from non-inflamed controls. However, methods other 
than flow cytometry might be applicable to gain deeper insights into the nature of the cells 
residing in the biliary tree, for example single cell sequencing. Such data could indicate an 
origin of these cells based on TCR sequencing, enabling the investigation of overlapping 
clonotypes that may also indicate antigen-driven expansions (265). Moreover, sequencing 
data may be used for pathway analysis or a comparison to reference datasets on T cells 
residing in other organs, such as the gut. We did not get the possibility to collect matched 
samples from inflamed and non-inflamed areas of the biliary tree and/or the gut to be able to 
link these results with clinical data. Future studies shall address immunological correlates 
with clinical characteristics of PSC patients in order to get further insights into the PSC 
pathogenesis. This knowledge may aid treatment development for PSC. 
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5 CONCLUDING REMARKS 
Lymphocytes, including NK cells and T cells, are important players in the human immune 
system. Relying on experimental model systems is not sufficient in order to understand 
immunological mechanisms in multifaceted human disease settings. Therefore, studying 
lymphocytes in human diseases will provide further insights. A summary of the key findings 
presented in this thesis are listed below: 
• NK cells are highly activated and proliferate in acute DENV infection, a response that 
is mainly confined to immature NK cell subsets, most likely driven by cytokines and 
uncoupled from NK cell education (paper I) 
• Responding NK cells exhibit a homing receptor profile indicating potential migration 
to peripheral tissues in acute DENV infection, particularly the skin (paper I) 
• As compared to healthy controls, NK cells and T cells exhibit phenotypical changes 
upon long-term NA treatment in HBeAg neative CHB patients with only minor 
phenotypical changes upon treatment cessation (paper II and III) 
• Stopping NA therapy in HBeAg negative CHB patients augments NK cell natural 
cytotoxicty responses, which coincides with liver damage and functional cure in a 
subset of patients (paper II) 
• Structured NA discontinuation improves the exhausted HBV-specifc T cell 
functionality in CHB, and this can be even further boosted upon PD-L1 blockade 
(paper III) 
• The MAIT cell compartment is affected in PSC patients with reduced frequencies and 
functional impairment in circulation, whereas levels of MAIT cells are retained within 
bile ducts, the tissue affected by PSC (paper IV) 
• The biliary immune system contains a substantial population of biliary-resident cells 
expressing CD69 and CD103 that differ in the immune compositon as compared to 
CD69-CD103- cells from bile ducts and immune cells from peripheral blood (paper 
V) 
• The main population of tissue-resident immune cells within bile ducts are TCRαβ 
CD8αβ+ effector memory T cells that co-express gut and liver homing receptors and 
possess a Th1/Th17 functional profile (paper V) 
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